ジェネリック医薬品市場レポート：2024-2034

Generic Drugs Market Report 2024-2034

レポート詳細ジェネリック医薬品市場レポート 2024-2034年：この調査レポートは、業界とその基礎となるダイナミクスをより良く理解することを望むなら、新たな収益ポケットを目指す大手企業にとっ... もっと見る

出版社	出版年月	電子版価格	ページ数	図表数	言語
Visiongain ヴィジョンゲイン社	2024年3月4日	GBP5,150 部署ライセンスライセンス・価格情報注文方法はこちら	357	356	英語

※上記価格は部署ライセンス（Departmental licence）価格です。
その他の価格についてはデータリソースまでお問合せください。
日本語のページは自動翻訳を利用し作成しています。
実際のレポートは英文のみでご納品いたします。

目次
図表リスト

サマリー

レポート詳細

ジェネリック医薬品市場レポート 2024-2034年：この調査レポートは、業界とその基礎となるダイナミクスをより良く理解することを望むなら、新たな収益ポケットを目指す大手企業にとって貴重なものとなるでしょう。また、異業種への進出や新規地域での既存事業の拡大を目指す企業にも有用です。

老年人口の増加とジェネリック医薬品の手頃な価格が業界の成長を促進する見通し
ジェネリック医薬品市場は、高齢者人口の増加、ジェネリック医薬品の手頃な価格と有効性といった主な要因によって大きく牽引されると予想される。世界の人口構造が高齢化へとシフトするにつれ、慢性疾患の有病率が高まり、長期的な治療が必要となる。ジェネリック医薬品は、先発医薬品と同等の治療効果があり、費用対効果が高いことで知られており、高齢者の医療ニーズを満たす重要なソリューションとして浮上している。ジェネリック医薬品の手頃な価格は、高齢者がしばしば直面する経済的制約に合致しており、普及を促進している。政府や医療制度は、ジェネリック医薬品の経済的メリットや利用しやすさを認識しており、市場成長をさらに促進する政策やイニシアチブを支援する可能性が高い。手頃な価格の治療を求める高齢者人口の増加とジェネリック医薬品の実証された有効性の組み合わせにより、同市場は医療の課題に対処し、必要不可欠な医薬品への幅広いアクセスを確保する上で極めて重要な役割を果たすことになります。

医薬品の副作用が市場成長の課題に
医薬品に伴う副作用は、ジェネリック医薬品市場にとって大きな課題となることが予想される。ジェネリック医薬品は先発医薬品の治療効果を再現することを目的としているが、画一的なアプローチでは患者の反応の個人差に十分に対応できない可能性がある。このような個別化された製剤の欠如は、患者が副作用や不十分な治療反応を経験する可能性があるため、潜在的な副作用に関する懸念を引き起こす。ジェネリック医薬品間のバイオアベイラビリティのばらつきはさらにシナリオを複雑にし、薬物濃度レベルのばらつきとそれに続く副作用につながる可能性がある。さらに、ジェネリック医薬品と先発医薬品との間の不活性成分の違いは、特にアレルギーや過敏症の患者にとって忍容性に影響を及ぼす可能性があり、標準化された製剤の必要性が生じている。ジェネリック医薬品の市販後調査は先発医薬品に比べて限定的であるため、副作用のタイムリーな特定と管理に課題があり、消費者の信頼に影響を与える。ジェネリック医薬品に関連するこれらの副作用に対処するためには、ジェネリック医薬品市場の持続的な成長と成功を確保するために、規制措置の強化、厳格な品質管理、個別化医療への注力が必要である。

市場調査レポートを購入する前にすべき質問とは？

ジェネリック医薬品市場はどのように進化しているのか？
何がジェネリック医薬品市場を牽引し、阻害しているのか？
ジェネリック医薬品の各サブマーケットは予測期間中にどのように成長し、2034年にはどれくらいの売上高を占めるようになるのか。
2024年から2034年にかけて、ジェネリック医薬品の各サブマーケットの市場シェアはどのように推移するのか？
2024年から2034年にかけて、市場全体を牽引する主な要因は何か？
主要なジェネリック医薬品市場はマクロ経済の動きに幅広く追随するのか、それとも個々の国市場が他を凌駕するのか。
2034年までに各国市場のシェアはどのように変化し、どの地域が2034年の市場をリードするのか。
主要プレーヤーと予測期間中の見通しは？
2024年から2034年の間に、業界はどのように進化するのか？ジェネリック医薬品のプロジェクトが現在、そして今後10年間にもたらす影響とは？
ジェネリック医薬品の市場規模をさらに拡大するために、製品化の必要性が高まっているのでしょうか？
ジェネリック医薬品市場はどこへ向かっているのか？
新商品や新サービスに最適な投資方法とは？
企業を新たな成長軌道に乗せ、C-suiteに移行させるための重要な展望とは？

ジェネリック医薬品市場が現在、そして今後10年間でどのような影響を受けるかを知る必要がある：

357ページに及ぶレポートには、133の表、223の図表が掲載されている。
本レポートでは、業界における主要な有利分野を取り上げているため、今すぐターゲットを絞ることができる。
世界、地域、国の売上高と成長に関する詳細な分析が含まれている。
競合他社が成功した主なトレンド、変化、収益予測をハイライトします。

本レポートは、ジェネリック医薬品市場が今後10年間でどのように発展していくのか、またCOVID-19の景気後退と好転の変動に合わせてどのように発展していくのかをお伝えします。ジェネリック医薬品市場は、過去10年間のどの時期よりも、今がより重要である。

2034年までの予測やその他の分析から、商業的な展望が明らかになる

2034年までの収益予測に加え、最近の実績、成長率、市場シェアも提供している。
ビジネスの展望や展開など、独自の分析が掲載されている。
質的分析（市場ダイナミクス、促進要因、機会、阻害要因、課題を含む）、コスト構造、ジェネリック医薬品価格上昇の影響、最近の動向をご覧いただけます。

本レポートには、COVID-19が業界と貴社にどのような影響を与えるかについてのデータ分析と貴重な洞察が含まれている。本レポートでは、COVID-19の4つの回復パターンとその影響、すなわち「V」、「L」、「W」、「U」について論じている。

レポート対象セグメント

タイプ

シンプルジェネリックス
スペシャリティジェネリック
バイオシミラー

投与経路

経口
非経口
トピカル
その他

適応症

中枢神経系（CNS）
腫瘍学
感染症
心血管疾患
消化器疾患
筋骨格系疾患
その他

薬剤クラス

抗生物質
抗ヒスタミン薬
鎮痛剤
降圧剤
抗糖尿病薬
解熱剤
その他

処方箋タイプ

処方箋ジェネリック
店頭販売（OTC）ジェネリック医薬品

流通チャネル

小売薬局
病院薬局
オンライン薬局
その他

世界市場全体とセグメント別の収益予測に加え、5つの地域と20の主要国市場の収益予測も掲載しています：

北米

米国
カナダ

欧州

ドイツ
英国
フランス
イタリア
スペイン
その他の欧州

アジア太平洋

中国
日本
インド
オーストラリア
韓国
その他のアジア太平洋

ラテンアメリカ

ブラジル
アルゼンチン
その他のラテンアメリカ

MEA

GCC諸国
南アフリカ
その他のMEA

また、2024年から2034年までのジェネリック医薬品市場における主要企業のプロファイルも掲載している。

主要企業と市場成長の可能性

Alkem Laboratories Ltd.
Amneal Pharmaceuticals LLC
Aurobindo Pharma
Biocon
Cipla Inc.
Dr. Reddy’s Laboratories Ltd.
Endo International plc
Lupin
Novartis AG
Sun Pharmaceuticals Industries Ltd.
Teva Pharmaceutical Industries Ltd.
Torrent Pharmaceuticals Ltd.
Viatris Inc.

2024年から2034年までのジェネリック医薬品市場全体の世界売上高（金額ベース）は、2024年に4,500億米ドルを突破する。2034年まで力強い収益成長を予測。当社の調査では、最も大きな可能性を秘めた組織を特定しています。彼らの能力、進歩、商業的展望を発見し、一歩先を行くお手伝いをします。

ジェネリック医薬品市場、2024-2034年レポートはどのようにお役に立ちますか？

要約すると、350ページを超えるこのレポートは、以下の知識を提供する：

ジェネリック医薬品市場の2024年から2034年までの収益予測（タイプ、処方タイプ、適応症、薬効分類、投与経路、流通経路の各予測を世界および地域レベルで掲載） - 業界の将来性を発見し、投資と収益に最も有利な場所を見つけることができます。
5つの地域と20の主要国市場の2034年までの収益予測 - 北米、欧州、アジア太平洋、中南米、MEAのジェネリック医薬品市場2024年から2034年までの市場予測をご覧ください。また、米国、カナダ、ブラジル、ドイツ、フランス、英国、イタリア、中国、インド、日本、オーストラリアなどの主要経済圏の市場も予測しています。
2024年から2034年までのジェネリック医薬品市場に関わる主要企業13社の企業プロファイルを含む。

独自の予測による定量的・定性的分析をご覧ください。私たちのレポートだけに含まれる情報を入手し、貴重なビジネスインテリジェンスで情報を得ることができます。

他にはない情報

私たちの新しいレポートがあれば、知識に遅れをとったり、チャンスを逃したりする可能性が低くなります。Visiongainの調査レポートが貴社の調査、分析、意思決定にどのように役立つかをご覧ください。Visiongainの調査は、ジェネリック医薬品市場、2024年から2034年、市場をリードする企業の商業分析を必要とするすべての人のためのものです。データ、トレンド、予測をご覧いただけます。

ページTOPに戻る

1 レポート概要
1.1 研究の目的
1.2 ジェネリック医薬品市場の紹介
1.3 本レポートの内容
1.4 本レポートを読むべき理由
1.5 本分析レポートが回答する主な質問
1.6 本レポートの対象者
1.7 方法論
1.7.1 市場の定義
1.7.2 市場評価・予測手法
1.7.3 データの検証
1.7.3.1 一次調査
1.7.3.2 セカンダリーリサーチ
1.8 よくある質問（FAQ）
1.9 Visiongainの関連レポート
1.10 Visiongainについて

2 エグゼクティブ・サマリー

3 市場概要
3.1 主要な調査結果
3.2 市場ダイナミクス
3.2.1 市場促進要因
3.2.1.1 ジェネリック医薬品のコストと有効性
3.2.1.2 ジェネリック医薬品メーカー間の戦略的パートナーシップ
3.2.1.3 老年人口の増加
3.2.1.4 慢性疾患の増加
3.2.1.5 ジェネリック医薬品を推進する政府のイニシアティブの高まり
3.2.2 市場抑制要因
3.2.2.1 厳しい政府規制
3.2.2.2 ブランド・ロイヤルティ
3.2.2.3 知的財産権訴訟と特許紛争
3.2.2.4 医薬品に関連する副作用
3.2.3 市場機会
3.2.3.1 この10年間におけるブロックバスター医薬品の特許切れ
3.2.3.2 生物製剤とバイオシミラーの成長
3.3 COVID-19の影響分析
3.4 ポーターのファイブフォース分析
3.4.1 サプライヤーの交渉力
3.4.2 買い手の交渉力
3.4.3 競争相手のライバル関係
3.4.4 代替品による脅威
3.4.5 新規参入企業の脅威
3.5 PEST分析
3.5.1 政治的要因
3.5.2 経済
3.5.3 社会
3.5.4 技術的

4 ジェネリック医薬品市場分析：タイプ別
4.1 主要な調査結果
4.2 タイプ別セグメント市場魅力度指数
4.3 ジェネリック医薬品のタイプ別市場規模推定と予測
4.4 単純後発医薬品
4.4.1 2024〜2034年の地域別市場規模（US$ Billion）
4.4.2 地域別市場シェア、2024年・2034年(%)
4.5 スペシャリティジェネリック
4.5.1 2024〜2034年の地域別市場規模（US$ Billion）
4.5.2 地域別市場シェア、2024年・2034年(%)
4.6 バイオシミラー
4.6.1 2024〜2034年の地域別市場規模（US$ Billion）
4.6.2 地域別市場シェア、2024年・2034年(%)

5 ジェネリック医薬品市場分析：処方タイプ別
5.1 主要調査結果
5.2 処方箋タイプ別セグメント市場魅力度指数
5.4 処方箋タイプ別ジェネリック医薬品市場規模の推定と予測
5.5 処方箋ジェネリック医薬品
5.5.1 2024〜2034年の地域別市場規模（US$ Billion）
5.5.2 地域別市場シェア、2024年・2034年(%)
5.6 OTCジェネリック医薬品
5.6.1 2024〜2034年の地域別市場規模（US$ Billion）
5.6.2 地域別市場シェア、2024年・2034年(%)

6 ジェネリック医薬品市場分析：適応症別
6.1 主な調査結果
6.2 適応症セグメント市場魅力度指数
6.4 ジェネリック医薬品の適応症別市場規模推定と予測
6.5 中枢神経系（CNS）
6.5.1 2024〜2034年の地域別市場規模（US$ Billion）
6.5.2 地域別市場シェア、2024年・2034年(%)
6.6 がん領域
6.6.1 2024〜2034年の地域別市場規模（US$ Billion）
6.6.2 地域別市場シェア、2024年・2034年(%)
6.7 感染症
6.7.1 2024〜2034年の地域別市場規模（US$ Billion）
6.7.2 地域別市場シェア、2024年・2034年(%)
6.8 循環器疾患
6.8.1 2024〜2034年の地域別市場規模（US$ Billion）
6.8.2 地域別市場シェア、2024年・2034年(%)
6.9 消化器疾患
6.9.1 2024〜2034年の地域別市場規模（US$ Billion）
6.9.2 地域別市場シェア、2024年・2034年(%)
6.10 筋骨格系疾患
6.10.1 2024〜2034年の地域別市場規模（US$ Billion）
6.10.2 地域別市場シェア、2024年・2034年(%)
6.11 その他
6.11.1 2024〜2034年の地域別市場規模（US$ Billion）
6.11.2 地域別市場シェア、2024年・2034年(%)

7 ジェネリック医薬品市場分析：薬剤クラス別
7.1 主要な調査結果
7.2 薬剤クラスセグメント市場魅力度指数
7.4 薬剤クラス別ジェネリック医薬品市場規模の推定と予測
7.5 抗生物質
7.5.1 地域別市場規模、2024年〜2034年（US$ Billion）
7.5.2 地域別市場シェア、2024年・2034年(%)
7.6 抗ヒスタミン薬
7.6.1 地域別市場規模、2024〜2034年（US$ Billion）
7.6.2 地域別市場シェア、2024年・2034年(%)
7.7 鎮痛薬
7.7.1 2024〜2034年の地域別市場規模（US$ Billion）
7.7.2 地域別市場シェア、2024年・2034年(%)
7.8 降圧剤
7.8.1 2024〜2034年の地域別市場規模（US$ Billion）
7.8.2 地域別市場シェア、2024年・2034年(%)
7.9 抗糖尿病薬
7.9.1 2024〜2034年の地域別市場規模（US$ Billion）
7.9.2 地域別市場シェア、2024年・2034年(%)
7.10 解熱剤
7.10.1 2024〜2034年地域別市場規模（US$ Billion）
7.10.2 地域別市場シェア、2024年・2034年(%)
7.11 その他
7.11.1 2024〜2034年地域別市場規模（US$ Billion）
7.11.2 地域別市場シェア、2024年・2034年(%)

8 ジェネリック医薬品市場分析：投与経路別
8.1 主要調査結果
8.2 投与経路セグメント市場魅力度指数
8.4 投与経路別ジェネリック医薬品市場規模の推定と予測
8.5 経口剤
8.5.1 2024〜2034年の地域別市場規模（US$ Billion）
8.5.2 地域別市場シェア、2024年・2034年(%)
8.6 非経口剤
8.6.1 2024〜2034年の地域別市場規模（US$ Billion）
8.6.2 地域別市場シェア、2024年・2034年(%)
8.7 外用剤
8.7.1 2024〜2034年の地域別市場規模（US$ Billion）
8.7.2 地域別市場シェア、2024年・2034年(%)
8.8 その他
8.8.1 2024〜2034年の地域別市場規模（US$ Billion）
8.8.2 地域別市場シェア、2024年・2034年(%)

9 ジェネリック医薬品市場分析：流通チャネル別
9.1 主要な調査結果
9.2 流通チャネルセグメント市場魅力度指数
9.4 流通チャネル別ジェネリック医薬品市場規模の推定と予測
9.5 病院薬局
9.5.1 2024〜2034年の地域別市場規模（US$ Billion）
9.5.2 地域別市場シェア、2024年・2034年(%)
9.6 小売薬局
9.6.1 2024〜2034年の地域別市場規模（US$ Billion）
9.6.2 地域別市場シェア、2024年・2034年(%)
9.7 オンライン薬局
9.7.1 2024〜2034年の地域別市場規模（US$ Billion）
9.7.2 地域別市場シェア、2024年・2034年(%)
9.8 その他
9.8.1 2024〜2034年の地域別市場規模（US$ Billion）
9.8.2 地域別市場シェア、2024年・2034年(%)

10 ジェネリック医薬品市場分析：地域別
10.1 主要な調査結果
10.3 地域別市場規模の推定と予測

11 北米のジェネリック医薬品市場分析
11.1 主要な調査結果
11.2 北米のジェネリック医薬品市場魅力度指数
11.3 北米のジェネリック医薬品市場国別推定、2024年、2029年、2034年（US$ Billion）
11.4 北米のジェネリック医薬品市場規模推定と予測：国別
11.5 北米のジェネリック医薬品市場規模推定と予測：タイプ別
11.6 北米のジェネリック医薬品市場規模推定と予測：投与経路別
11.7 北米のジェネリック医薬品市場規模推定と予測：適応症別
11.8 北米のジェネリック医薬品市場規模推定と予測：薬効クラス別
11.9 北米のジェネリック医薬品市場規模推定と予測：処方タイプ別
11.10 北米のジェネリック医薬品市場規模推定と予測：流通チャネル別
11.11 アメリカのジェネリック医薬品市場分析
11.12 カナダのジェネリック医薬品市場分析

12 欧州のジェネリック医薬品市場分析
12.1 主要な調査結果
12.2 欧州のジェネリック医薬品市場魅力度指数
12.3 欧州のジェネリック医薬品市場国別推定、2024年、2029年、2034年（US$ Billion）
12.4 欧州のジェネリック医薬品市場規模推定と予測：国別
12.5 欧州のジェネリック医薬品市場規模推定と予測：タイプ別
12.6 欧州のジェネリック医薬品市場規模推定と予測：投与経路別
12.7 欧州のジェネリック医薬品市場規模推定と予測：適応症別
12.8 欧州のジェネリック医薬品市場規模推定と予測：薬効クラス別
12.9 欧州のジェネリック医薬品市場規模推定と予測：処方タイプ別
12.10 欧州のジェネリック医薬品市場規模推定と予測：流通チャネル別
12.11 ドイツのジェネリック医薬品市場分析
12.12 イギリスのジェネリック医薬品市場分析
12.13 フランスのジェネリック医薬品市場分析
12.14 イタリアのジェネリック医薬品市場分析
12.15 スペインのジェネリック医薬品市場分析
12.16 その他の欧州のジェネリック医薬品市場分析

13 アジア太平洋地域のジェネリック医薬品市場分析
13.1 主要な調査結果
13.2 アジア太平洋地域のジェネリック医薬品市場魅力度指数
13.3 アジア太平洋地域のジェネリック医薬品市場の国別推移、2024年、2029年、2034年（US$ Billion）
13.4 アジア太平洋地域のジェネリック医薬品市場規模推定と予測：国別
13.5 アジア太平洋地域のジェネリック医薬品市場規模推定と予測：タイプ別
13.6 アジア太平洋地域のジェネリック医薬品市場規模推定と予測：投与経路別
13.7 アジア太平洋地域のジェネリック医薬品市場規模推定と予測：適応症別
13.8 アジア太平洋地域のジェネリック医薬品市場規模推定と予測：薬効クラス別
13.9 アジア太平洋地域のジェネリック医薬品市場規模推定と予測：処方タイプ別
13.10 アジア太平洋地域のジェネリック医薬品市場規模推定と予測：流通チャネル別
13.11 日本のジェネリック医薬品市場分析
13.12 中国のジェネリック医薬品市場分析
13.13 インドのジェネリック医薬品市場分析
13.14 オーストラリアのジェネリック医薬品市場分析
13.15 韓国ジェネリック医薬品市場の分析
13.16 その他のアジア太平洋地域のジェネリック医薬品市場分析

1 4 ラテンアメリカのジェネリック医薬品市場分析
14.1 主要な調査結果
14.2 ラテンアメリカのジェネリック医薬品市場魅力度指数
14.3 ラテンアメリカのジェネリック医薬品国別市場、2024年、2029年、2034年（US$ Billion）
14.4 ラテンアメリカのジェネリック医薬品市場規模推定と予測：国別
14.5 ラテンアメリカのジェネリック医薬品市場規模推定と予測：タイプ別
14.6 ラテンアメリカのジェネリック医薬品市場規模推定と予測：投与経路別
14.7 ラテンアメリカのジェネリック医薬品市場規模推定と予測：適応症別
14.8 ラテンアメリカのジェネリック医薬品市場規模推定と予測：薬効クラス別
14.9 ラテンアメリカのジェネリック医薬品市場規模推定と予測：処方タイプ別
14.10 ラテンアメリカのジェネリック医薬品市場規模推定と予測：流通チャネル別
14.11 ブラジルのジェネリック医薬品市場分析
14.12 アルゼンチンのジェネリック医薬品市場分析
14.13 その他のラテンアメリカのジェネリック医薬品市場分析

15 MEAのジェネリック医薬品市場分析
15.1 主要な調査結果
15.2 MEAのジェネリック医薬品市場魅力度指数
15.3 MEAのジェネリック医薬品国別市場、2024年、2029年、2034年（US$ Billion）
15.4 MEAのジェネリック医薬品市場規模推定と予測：国別
15.5 MEAのジェネリック医薬品市場規模推定と予測：タイプ別
15.6 MEAのジェネリック医薬品市場規模推定と予測：投与経路別
15.7 MEAのジェネリック医薬品市場規模推定と予測：適応症別
15.8 MEAのジェネリック医薬品市場規模推定と予測：薬効クラス別
15.9 MEAのジェネリック医薬品市場規模推定と予測：処方タイプ別
15.10 MEAのジェネリック医薬品市場規模推定と予測：流通チャネル別
15.11 GCCのジェネリック医薬品市場分析
15.12 南アフリカのジェネリック医薬品市場分析
15.13 その他のMEAのジェネリック医薬品市場分析

16 会社概要
16.1 競争環境、2023年
16.2 Novartis AG
16.2.1 会社概要
16.2.2 会社概要
16.2.3 財務分析
16.2.3.1 純収入、2018-2022年
16.2.3.2 地域市場シェア（2022年
16.2.3.3 研究開発費、2018年～2022年
16.2.5 製品ベンチマーク
16.2.6 戦略的展望
16.3 Teva Pharmaceutical Industries Ltd.
16.3.1 会社概要
16.3.2 会社概要
16.3.3 財務分析
16.3.3.1 売上高、2018-2022年
16.3.3.2 地域市場シェア、2022年
16.3.3.3 研究開発費、2018年～2022年
16.3.5 製品ベンチマーク
16.3.6 戦略的展望
16.4 Viatris Inc.
16.4.1 会社概要
16.4.2 会社概要
16.4.3 財務分析
16.4.3.1 売上高、2018-2022年
16.4.3.2 地域市場シェア、2022年
16.4.3.3 研究開発費、2018年～2022年
16.4.5 製品ベンチマーク
16.4.6 戦略的展望
16.5 Lupin
16.5.1 会社概要
16.5.2 会社概要
16.5.3 財務分析
16.5.3.1 売上高、2018-2022年
16.5.3.2 研究開発費、2018年～2022年
16.5.5 製品ベンチマーク
16.5.6 戦略的展望
16.6 Alkem Laboratories Ltd.
16.6.1 会社概要
16.6.2 会社概要
16.6.3 財務分析
16.6.3.1 純収入、2018-2022年
16.6.3.2 地域市場シェア、2022年
16.6.3.3 研究開発費、2018-2022年
16.6.4 製品ベンチマーク
16.6.5 戦略的展望
16.7 Cipla Inc.
16.7.1 会社概要
16.7.2 会社概要
16.7.3 財務分析
16.7.3.1 売上高、2018年～2022年
16.7.3.2 地域市場シェア、2022年
16.7.3.3 研究開発費、2018年～2022年
16.7.5 製品ベンチマーク
16.7.6 戦略的展望
16.8 Biocon
16.8.1 会社概要
16.8.2 会社概要
16.8.3 財務分析
16.8.3.1 売上高、2018年～2022年
16.8.3.2 セグメント別市場シェア、2022年
16.8.3.3 研究開発費、2018-2022年
16.8.5 製品ベンチマーク
16.8.6 戦略的展望
16.9 Aurobindo Pharma
16.9.1 会社概要
16.9.2 会社概要
16.9.3 財務分析
16.9.3.1 売上高、2018年～2022年
16.9.4 製品ベンチマーク
16.9.5 戦略的展望
16.10 Endo International plc
16.10.1 会社概要
16.10.2 会社概要
16.10.3 財務分析
16.10.3.1 売上高、2018年～2022年
16.10.3.2 研究開発費、2018年～2022年
16.10.4 製品ベンチマーク
16.10.5 戦略的展望
16.11 Torrent Pharmaceuticals Ltd.
16.11.1 会社概要
16.11.2 会社概要
16.11.3 財務分析
16.11.3.1 売上高、2018年～2022年
16.11.3.2 地域市場シェア、2022年
16.11.4 製品ベンチマーク
16.12 Amneal Pharmaceuticals LLC
16.12.1 会社概要
16.12.2 会社概要
16.12.3 財務分析
16.12.3.1 収益、2018-2022年
16.12.3.2 研究開発費、2018-2022年
16.12.4 製品ベンチマーク
16.12.5 戦略的展望
16.13 Dr. Reddy’s Laboratories Ltd.
16.13.1 会社概要
16.13.2 会社概要
16.13.3 財務分析
16.13.3.1 売上高、2018年～2022年
16.13.3.2 地域市場シェア、2022年
16.13.3.3 研究開発費、2018年〜2022年
16.13.4 製品ベンチマーク
16.13.5 戦略的展望
16.14 Sun Pharmaceutical Industries Ltd.
16.14.1 会社概要
16.14.2 会社概要
16.14.3 財務分析
16.14.3.1 収益、2018-2022年
16.14.3.2 研究開発費、2018-2022年
16.14.4 製品ベンチマーク
16.14.5 戦略的展望

17 結論と提言
17.1 Visiongainからの結びの言葉
17.2 市場プレイヤーへの提言

ページTOPに戻る

図表リスト

表の一覧
Table 1 Generic Drugs Market Snapshot, 2024 & 2034 (US$ billion, CAGR %)
Table 2 Patent Expiration
Table 3 Global Generic Drugs Market Forecast by Region 2024-2034 (US$ Billion, AGR%, CAGR%): "V" Shaped Recovery
Table 4 Generic Drugs Market Forecast by Region 2024-2034 (US$ Billion, AGR%, CAGR%): "U" Shaped Recovery
Table 5 Global Generic Drugs Market Forecast by Region 2024-2034 (US$ Billion, AGR%, CAGR%): "W" Shaped Recovery
Table 6 Global Generic Drugs Market Forecast by Region 2024-2034 (US$ Billion, AGR%, CAGR%): "L" Shaped Recovery
Table 7 Generic Drugs Market Forecast by Type, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 8 Simple Generics Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 9 Specialty Generics Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 10 Biosimilars Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 11 Generic Drugs Market Forecast by Type, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 12 Prescription Generics Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 13 Over-the-Counter (OTC) Generics Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 14 Generic Drugs Market Forecast by Indication, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 15 Central Nervous System (CNS) Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 16 Oncology Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 17 Infectious Diseases Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 18 Cardiovascular Diseases Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 19 Gastrointestinal Diseases Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 20 Musculoskeletal Diseases Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 21 Others Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 22 Generic Drugs Market Forecast by Drug Class, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 23 Antibiotics Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 24 Antihistamines Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 25 Analgesics Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 26 Antihypertensive Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 27 Antidiabetic Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 28 Antipyretic Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 29 Others Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 30 Generic Drugs Market Forecast by Route of Administration, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 31 Oral Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 32 Parenteral Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 33 Topical Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 34 Others Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 35 Generic Drugs Market Forecast by Distribution Channel, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 36 Hospital Pharmacies Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 37 Retail Pharmacies Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 38 Online Pharmacies Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 39 Others Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 40 Global Generic drugs Market Forecast by Region 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 41 North America Generic Drugs Market Forecast by Country, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 42 North America Generic Drugs Market Forecast by Type, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 43 North America Generic Drugs Market Forecast by Route of Administration, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 44 North America Generic Drugs Market Forecast by Indication, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 45 North America Generic Drugs Market Forecast by Drug Class, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 46 North America Generic drugs Market Forecast by Prescription Type, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 47 North America Generic Drugs Market Forecast by Distribution Channel, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 48 U.S. Generic Drugs Market Forecast by Country, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 49 Canada Generic Drugs Market Forecast by Country, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 50 Europe Generic Drugs Market Forecast by Country, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 51 Europe Generic Drugs Market Forecast by Type, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 52 Europe Generic Drugs Market Forecast by Route of Administration, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 53 Europe Generic Drugs Market Forecast by Indication, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 54 Europe Generic Drugs Market Forecast by Drug Class, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 55 Europe Generic drugs Market Forecast by Prescription Type, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 56 Europe Generic Drugs Market Forecast by Distribution Channel, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 57 Germany Generic Drugs Market Forecast by Country, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 58 UK Generic Drugs Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 59 France Generic Drugs Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 60 Italy Generic Drugs Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 61 Spain Generic Drugs Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 62 Rest of Europe Generic Drugs Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 63 Asia Pacific Generic Drugs Market Forecast by Country, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 64 Asia Pacific Generic Drugs Market Forecast by Type, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 65 Asia Pacific Generic Drugs Market Forecast by Route of Administration, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 66 Asia Pacific Generic Drugs Market Forecast by Indication, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 67 Asia Pacific Generic Drugs Market Forecast by Drug Class, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 68 Asia Pacific Generic drugs Market Forecast by Prescription Type, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 69 Asia Pacific Generic Drugs Market Forecast by Distribution Channel, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 70 Japan Generic Drugs Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 71 China Generic Drugs Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 72 India Generic Drugs Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 73 Australia Generic Drugs Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 74 South Korea Generic Drugs Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 75 Rest of Asia-Pacific Generic Drugs Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 76 Latin America Generic Drugs Market Forecast by Country, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 77 Latin America Generic Drugs Market Forecast by Type, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 78 Latin America Generic Drugs Market Forecast by Route of Administration, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 79 Latin America Generic Drugs Market Forecast by Indication, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 80 Latin America Generic Drugs Market Forecast by Drug Class, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 81 Latin America Generic drugs Market Forecast by Prescription Type, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 82 Latin America Generic Drugs Market Forecast by Distribution Channel, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 83 Brazil Generic Drugs Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 84 Argentina Generic Drugs Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 85 Rest of Latin America Generic Drugs Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 86 MEA Generic Drugs Market Forecast by Country, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 87 MEA Generic Drugs Market Forecast by Type, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 88 MEA Generic Drugs Market Forecast by Route of Administration, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 89 MEA Generic Drugs Market Forecast by Indication, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 90 MEA Generic Drugs Market Forecast by Drug Class, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 91 MEA Generic drugs Market Forecast by Prescription Type, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 92 MEA Generic Drugs Market Forecast by Distribution Channel, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 93 GCC Generic Drugs Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 94 South Africa Generic Drugs Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 95 Rest of MEA Generic Drugs Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 96 Novartis AG: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 97 Novartis AG: Product Benchmarking
Table 98 Novartis AG: Strategic Outlook
Table 99 Teva Pharmaceutical Industries Ltd.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 100 Teva Pharmaceutical Industries Ltd.: Product Benchmarking
Table 101 Teva Pharmaceutical Industries Ltd.: Strategic Outlook
Table 102 Viatris Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 103 Viatris Inc.: Product Benchmarking
Table 104 Viatris Inc.: Strategic Outlook
Table 105 Lupin: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 106 Lupin: Product Benchmarking
Table 107 Lupin: Strategic Outlook
Table 108 Alkem Laboratories Ltd.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 109 Alkem Laboratories Ltd.: Product Benchmarking
Table 110 Alkem Laboratories Ltd.: Strategic Outlook
Table 111 Cipla Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 112 Cipla Inc.: Product Benchmarking
Table 113 Cipla Inc.: Strategic Outlook
Table 114 Biocon: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 115 Biocon: Product Benchmarking
Table 116 Biocon: Strategic Outlook
Table 117 Aurobindo Pharma: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 118 Aurobindo Pharma: Product Benchmarking
Table 119 Aurobindo Pharma: Strategic Outlook
Table 120 Endo International plc: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 121 Endo International plc: Product Benchmarking
Table 122 Endo International plc: Strategic Outlook
Table 123 Torrent Pharmaceuticals Ltd.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 124 Torrent Pharmaceuticals Ltd.: Product Benchmarking
Table 125 Amneal Pharmaceuticals LLC: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 126 Amneal Pharmaceuticals LLC: Product Benchmarking
Table 127 Amneal Pharmaceuticals LLC: Strategic Outlook
Table 128 Dr. Reddy’s Laboratories Ltd.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 129 Dr. Reddy’s Laboratories Ltd.: Product Benchmarking
Table 130 Dr. Reddy’s Laboratories Ltd.: Strategic Outlook
Table 131 Sun Pharmaceutical Industries Ltd.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 132 Sun Pharmaceutical Industries Ltd.: Product Benchmarking
Table 133 Sun Pharmaceutical Industries Ltd.: Strategic Outlook

図の一覧
Figure 1 Generic Drugs Market Segmentation
Figure 2 Generic Drugs Market by Type: Market Attractiveness Index
Figure 3 Generic Drugs Market Forecast by Route of Administration: Market Attractiveness Index
Figure 4 Generic Drugs Market Forecast by Indication: Market Attractiveness Index
Figure 5 Generic Drugs Market Forecast by Indication: Market Attractiveness Index
Figure 6 Generic Drugs Market Forecast by Prescription Type: Market Attractiveness Index
Figure 7 Generic Drugs Market Forecast by Distribution Channel: Market Attractiveness Index
Figure 8 Generic Drugs Market Attractiveness Index by Region
Figure 9 Global Generic Drugs Market: Market Dynamics
Figure 10 Generic Drugs Market by Region, 2024-2034 (US$ Billion, AGR (%), CAGR (%)): “V” Shaped Recovery
Figure 11 Generic Drugs Market by Region, 2024-2034 (US$ Billion, AGR (%), CAGR (%)): “U” Shaped Recovery
Figure 12 Generic Drugs Market by Region, 2024-2034 (US$ Billion, AGR (%), CAGR (%)): “W” Shaped Recovery
Figure 13 Generic Drugs Market by Region, 2024-2034 (US$ Billion, AGR (%), CAGR (%)): “L” Shaped Recovery
Figure 14 Generic drugs Market: Porter’s Five Forces Analysis
Figure 15 Generic Drugs Market: PEST Analysis
Figure 16 Generic Drugs Market Forecast by Type: Market Attractiveness Index
Figure 17 Generic Drugs Market Forecast by Type, 2024-2034 (US$ Billion)
Figure 18 Generic Drugs Market Share Forecast by Type, 2024, 2029, 2034 (%)
Figure 19 Simple Generics Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
Figure 20 Simple Generics Market Share Forecast by Region, 2024 & 2034 (%)
Figure 21 Specialty Generics Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
Figure 22 Specialty Generics Market Share Forecast by Region, 2024 & 2034 (%)
Figure 23 Biosimilars Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
Figure 24 Biosimilars Market Share Forecast by Region, 2024 & 2034 (%)
Figure 25 Generic Drugs Market Forecast by Prescription Type: Market Attractiveness Index
Figure 26 Generic Drugs Market Forecast By Prescription Type, 2024-2034 (US$ Billion, AGR %)
Figure 27 Generic Drugs Market Share Forecast by Prescription Type, 2024, 2029, 2034 (%)
Figure 28 Prescription Generics Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
Figure 29 Prescription Generics Market Share Forecast by Region, 2024 & 2034 (%)
Figure 30 Over-the-Counter (OTC) Generics Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
Figure 31 Over-the-Counter (OTC) Generics Market Share Forecast by Region, 2024 & 2034 (%)
Figure 32 Generic Drugs Market Forecast by Indication: Market Attractiveness Index
Figure 33 Generic Drugs Market Forecast By Indication, 2024-2034 (US$ Billion, AGR %)
Figure 34 Generic Drugs Market Share Forecast by Indication, 2024, 2029, 2034 (%)
Figure 35 Central Nervous System (CNS) Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
Figure 36 Central Nervous System (CNS) Market Share Forecast by Region, 2024 & 2034 (%)
Figure 37 Oncology Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
Figure 38 Oncology Market Share Forecast by Region, 2024 & 2034 (%)
Figure 39 Infectious Diseases Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
Figure 40 Infectious Diseases Market Share Forecast by Region, 2024 & 2034 (%)
Figure 41 Cardiovascular Diseases Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
Figure 42 Cardiovascular Diseases Market Share Forecast by Region, 2024 & 2034 (%)
Figure 43 Gastrointestinal Diseases Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
Figure 44 Gastrointestinal Diseases Market Share Forecast by Region, 2024 & 2034 (%)
Figure 45 Musculoskeletal Diseases Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
Figure 46 Musculoskeletal Diseases Market Share Forecast by Region, 2024 & 2034 (%)
Figure 47 Others Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
Figure 48 Others Market Share Forecast by Region, 2024 & 2034 (%)
Figure 49 Generic Drugs Market Forecast by Drug Class: Market Attractiveness Index
Figure 50 Generic Drugs Market Forecast By Drug Class, 2024-2034 (US$ Billion, AGR %)
Figure 51 Generic Drugs Market Share Forecast by Drug Class, 2024, 2029, 2034 (%)
Figure 52 Antibiotics Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
Figure 53 Antibiotics Market Share Forecast by Region, 2024 & 2034 (%)
Figure 54 Antihistamines Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
Figure 55 Antihistamines Market Share Forecast by Region, 2024 & 2034 (%)
Figure 56 Analgesics Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
Figure 57 Analgesics Market Share Forecast by Region, 2024 & 2034 (%)
Figure 58 Antihypertensive Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
Figure 59 Antihypertensive Market Share Forecast by Region, 2024 & 2034 (%)
Figure 60 Antidiabetic Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
Figure 61 Antidiabetic Market Share Forecast by Region, 2024 & 2034 (%)
Figure 62 Antipyretic Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
Figure 63 Antipyretic Market Share Forecast by Region, 2024 & 2034 (%)
Figure 64 Others Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
Figure 65 Others Market Share Forecast by Region, 2024 & 2034 (%)
Figure 66 Generic Drugs Market Forecast by Route of Administration: Market Attractiveness Index
Figure 67 Generic Drugs Market Forecast By Route of Administration, 2024-2034 (US$ Billion, AGR %)
Figure 68 Generic Drugs Market Share Forecast by Route of Administration, 2024, 2029, 2034 (%)
Figure 69 Oral Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
Figure 70 Oral Market Share Forecast by Region, 2024 & 2034 (%)
Figure 71 Parenteral Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
Figure 72 Parenteral Market Share Forecast by Region, 2024 & 2034 (%)
Figure 73 Topical Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
Figure 74 Topical Market Share Forecast by Region, 2024 & 2034 (%)
Figure 75 Others Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
Figure 76 Others Market Share Forecast by Region, 2024 & 2034 (%)
Figure 77 Generic Drugs Market Forecast by Distribution Channel: Market Attractiveness Index
Figure 78 Generic Drugs Market Forecast By Distribution Channel, 2024-2034 (US$ Billion, AGR %)
Figure 79 Generic Drugs Market Share Forecast by Distribution Channel, 2024, 2029, 2034 (%)
Figure 80 Hospital Pharmacies Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
Figure 81 Hospital Pharmacies Market Share Forecast by Region, 2024 & 2034 (%)
Figure 82 Retail Pharmacies Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
Figure 83 Retail Pharmacies Market Share Forecast by Region, 2024 & 2034 (%)
Figure 84 Online Pharmacies Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
Figure 85 Online Pharmacies Market Share Forecast by Region, 2024 & 2034 (%)
Figure 86 Others Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
Figure 87 Others Market Share Forecast by Region, 2024 & 2034 (%)
Figure 88 Generic Drugs Market Forecast by Region, 2024 & 2034 (Revenue, CAGR%)
Figure 89 Generic Drugs Market Share Forecast by Region 2024, 2029, 2034(%)
Figure 90 Generic Drugs Market by Region, 2024-2034 (US$ Billion, AGR (%), CAGR (%))
Figure 91 North America Generic Drugs Market Attractiveness Index
Figure 92 North America Generic Drugs Market by Region, 2024, 2029 & 2034 (US$ Billion)
Figure 93 North America Generic Drugs Market Forecast by Country, 2024-2034 (US$ Billion, AGR %)
Figure 94 North America Generic Drugs Market Share Forecast by Country, 2024 & 2034 (%)
Figure 95 North America Generic Drugs Market Forecast by Type, 2024-2034 (US$ Billion, AGR %)
Figure 96 North America Generic Drugs Market Share Forecast by Type, 2024 & 2034 (%)
Figure 97 North America Generic Drugs Market Forecast by Route of Administration, 2024-2034 (US$ Billion, AGR %)
Figure 98 North America Generic Drugs Market Share Forecast by Route of Administration, 2024 & 2034 (%)
Figure 99 North America Generic Drugs Market Forecast by Indication, 2024-2034 (US$ Billion, AGR %)
Figure 100 North America Generic Drugs Market Share Forecast by Indication, 2024 & 2034 (%)
Figure 101 North America Generic Drugs Market Forecast by Drug Class, 2024-2034 (US$ Billion, AGR %)
Figure 102 North America Generic Drugs Market Share Forecast by Drug Class, 2024 & 2034 (%)
Figure 103 North America Generic Drugs Market Forecast by Prescription Type, 2024-2034 (US$ Billion, AGR %)
Figure 104 North America Generic Drugs Market Share Forecast by Prescription Type, 2024 & 2034 (%)
Figure 105 North America Generic Drugs Market Forecast by Distribution Channel, 2024-2034 (US$ Billion, AGR %)
Figure 106 North America Generic Drugs Market Share Forecast by Distribution Channel, 2024 & 2034 (%)
Figure 107 U.S. Generic Drugs Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 108 Canada Generic Drugs Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 109 Europe Generic Drugs Market Attractiveness Index
Figure 110 Europe Generic Drugs Market by Region, 2024, 2029 & 2034 (US$ Billion)
Figure 111 Europe Generic Drugs Market Forecast by Country, 2024-2034 (US$ Billion, AGR %)
Figure 112 Europe Generic Drugs Market Share Forecast by Country, 2024 & 2034 (%)
Figure 113 Europe Generic Drugs Market Forecast by Type, 2024-2034 (US$ Billion, AGR %)
Figure 114 Europe Generic Drugs Market Share Forecast by Type, 2024 & 2034 (%)
Figure 115 Europe Generic Drugs Market Forecast by Route of Administration, 2024-2034 (US$ Billion, AGR %)
Figure 116 Europe Generic Drugs Market Share Forecast by Route of Administration, 2024 & 2034 (%)
Figure 117 Europe Generic Drugs Market Forecast by Indication, 2024-2034 (US$ Billion, AGR %)
Figure 118 Europe Generic Drugs Market Share Forecast by Indication, 2024 & 2034 (%)
Figure 119 Europe Generic Drugs Market Forecast by Drug Class, 2024-2034 (US$ Billion, AGR %)
Figure 120 Europe Generic Drugs Market Share Forecast by Drug Class, 2024 & 2034 (%)
Figure 121 Europe Generic Drugs Market Forecast by Prescription Type, 2024-2034 (US$ Billion, AGR %)
Figure 122 Europe Generic Drugs Market Share Forecast by Prescription Type, 2024 & 2034 (%)
Figure 123 Europe Generic Drugs Market Forecast by Distribution Channel, 2024-2034 (US$ Billion, AGR %)
Figure 124 Europe Generic Drugs Market Share Forecast by Distribution Channel, 2024 & 2034 (%)
Figure 125 Germany Generic Drugs Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 126 U.K. Generic Drugs Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 127 France Generic Drugs Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 128 Italy Generic Drugs Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 129 Spain Generic Drugs Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 130 Rest of Europe Generic Drugs Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 131 Asia Pacific Generic Drugs Market Attractiveness Index
Figure 132 Asia Pacific Generic Drugs Market by Region, 2024, 2029 & 2034 (US$ Billion)
Figure 133 Asia Pacific Generic Drugs Market Forecast by Country, 2024-2034 (US$ Billion, AGR %)
Figure 134 Asia Pacific Generic Drugs Market Share Forecast by Country, 2024 & 2034 (%)
Figure 135 Asia Pacific Generic Drugs Market Forecast by Type, 2024-2034 (US$ Billion, AGR %)
Figure 136 Asia Pacific Generic Drugs Market Share Forecast by Type, 2024 & 2034 (%)
Figure 137 Asia Pacific Generic Drugs Market Forecast by Route of Administration, 2024-2034 (US$ Billion, AGR %)
Figure 138 Asia Pacific Generic Drugs Market Share Forecast by Route of Administration, 2024 & 2034 (%)
Figure 139 Asia Pacific Generic Drugs Market Forecast by Indication, 2024-2034 (US$ Billion, AGR %)
Figure 140 Asia Pacific Generic Drugs Market Share Forecast by Indication, 2024 & 2034 (%)
Figure 141 Asia Pacific Generic Drugs Market Forecast by Drug Class, 2024-2034 (US$ Billion, AGR %)
Figure 142 Asia Pacific Generic Drugs Market Share Forecast by Drug Class, 2024 & 2034 (%)
Figure 143 Asia Pacific Generic Drugs Market Forecast by Prescription Type, 2024-2034 (US$ Billion, AGR %)
Figure 144 Asia Pacific Generic Drugs Market Share Forecast by Prescription Type, 2024 & 2034 (%)
Figure 145 Asia Pacific Generic Drugs Market Forecast by Distribution Channel, 2024-2034 (US$ Billion, AGR %)
Figure 146 Asia Pacific Generic Drugs Market Share Forecast by Distribution Channel, 2024 & 2034 (%)
Figure 147 Japan Generic Drugs Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 148 China Generic Drugs Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 149 India Generic Drugs Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 150 Australia Generic Drugs Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 151 South Korea Generic Drugs Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 152 Rest of Asia Pacific Generic Drugs Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 153 Latin America Generic Drugs Market Attractiveness Index
Figure 154 Latin America Generic Drugs Market by Region, 2024, 2029 & 2034 (US$ Billion)
Figure 155 Latin America Generic Drugs Market Forecast by Country, 2024-2034 (US$ Billion, AGR %)
Figure 156 Latin America Generic Drugs Market Share Forecast by Country, 2024 & 2034 (%)
Figure 157 Latin America Generic Drugs Market Forecast by Type, 2024-2034 (US$ Billion, AGR %)
Figure 158 Latin America Generic Drugs Market Share Forecast by Type, 2024 & 2034 (%)
Figure 159 Latin America Generic Drugs Market Forecast by Route of Administration, 2024-2034 (US$ Billion, AGR %)
Figure 160 Latin America Generic Drugs Market Share Forecast by Route of Administration, 2024 & 2034 (%)
Figure 161 Latin America Generic Drugs Market Forecast by Indication, 2024-2034 (US$ Billion, AGR %)
Figure 162 Latin America Generic Drugs Market Share Forecast by Indication, 2024 & 2034 (%)
Figure 163 Latin America Generic Drugs Market Forecast by Drug Class, 2024-2034 (US$ Billion, AGR %)
Figure 164 Latin America Generic Drugs Market Share Forecast by Drug Class, 2024 & 2034 (%)
Figure 165 Latin America Generic Drugs Market Forecast by Prescription Type, 2024-2034 (US$ Billion, AGR %)
Figure 166 Latin America Generic Drugs Market Share Forecast by Prescription Type, 2024 & 2034 (%)
Figure 167 Latin America Generic Drugs Market Forecast by Distribution Channel, 2024-2034 (US$ Billion, AGR %)
Figure 168 Latin America Generic Drugs Market Share Forecast by Distribution Channel, 2024 & 2034 (%)
Figure 169 Brazil Generic Drugs Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 170 Argentina Generic Drugs Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 171 Rest of Latin America Generic Drugs Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 172 MEA Generic Drugs Market Attractiveness Index
Figure 173 MEA Generic Drugs Market by Region, 2024, 2029 & 2034 (US$ Billion)
Figure 174 MEA Generic Drugs Market Forecast by Country, 2024-2034 (US$ Billion, AGR %)
Figure 175 MEA Generic Drugs Market Share Forecast by Country, 2024 & 2034 (%)
Figure 176 MEA Generic Drugs Market Forecast by Type, 2024-2034 (US$ Billion, AGR %)
Figure 177 MEA Generic Drugs Market Share Forecast by Type, 2024 & 2034 (%)
Figure 178 MEA Generic Drugs Market Forecast by Route of Administration, 2024-2034 (US$ Billion, AGR %)
Figure 179 MEA Generic Drugs Market Share Forecast by Route of Administration, 2024 & 2034 (%)
Figure 180 MEA Generic Drugs Market Forecast by Indication, 2024-2034 (US$ Billion, AGR %)
Figure 181 MEA Generic Drugs Market Share Forecast by Indication, 2024 & 2034 (%)
Figure 182 MEA Generic Drugs Market Forecast by Drug Class, 2024-2034 (US$ Billion, AGR %)
Figure 183 MEA Generic Drugs Market Share Forecast by Drug Class, 2024 & 2034 (%)
Figure 184 MEA Generic Drugs Market Forecast by Prescription Type, 2024-2034 (US$ Billion, AGR %)
Figure 185 MEA Generic Drugs Market Share Forecast by Prescription Type, 2024 & 2034 (%)
Figure 186 MEA Generic Drugs Market Forecast by Distribution Channel, 2024-2034 (US$ Billion, AGR %)
Figure 187 MEA Generic Drugs Market Share Forecast by Distribution Channel, 2024 & 2034 (%)
Figure 188 GCC Generic Drugs Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 189 South Africa Generic Drugs Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 190 Rest of MEA Generic Drugs Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 191 Generic Drugs Market: Company Share Analysis, 2023
Figure 192 Novartis AG: Net Revenue, 2018-2022 (US$ Million, AGR%)
Figure 193 Novartis AG: Regional Market Shares, 2022
Figure 194 Novartis AG: R&D Expense, 2018-2022 (US$ Million, AGR%)
Figure 195 Teva Pharmaceutical Industries Ltd.: Annual Revenue, 2018-2022 (US$ million, AGR%)
Figure 196 Teva Pharmaceutical Industries Ltd: Regional Market Shares, 2022
Figure 197 Teva Pharmaceutical Industries Ltd.: R&D Expense, 2018-2022 (US$ Million, AGR%)
Figure 198 Viatris Inc.: Annual Revenue, 2018-2022 (US$ Million, AGR%)
Figure 199 Viatris Inc.: Regional Market Shares, 2022
Figure 200 Viatris Inc.: R&D Expense, 2018-2022 (US$ Million, AGR%)
Figure 201 Lupin: Net Revenue, 2018-2022 (US$ Million, AGR%)
Figure 202 Lupin: R&D Expense, 2018-2022 (US$ Million, AGR%)
Figure 203 Alkem Laboratories Ltd.: Net Revenue, 2018-2022 (US$ Million, AGR%)
Figure 204 Alkem Laboratories Ltd.: Regional Market Shares, 2022
Figure 205 Alkem Laboratories Ltd.: R&D Expense, 2018-2022 (US$ Million, AGR%)
Figure 206 Cipla Inc.: Net Revenue, 2018-2022 (US$ Million, AGR%)
Figure 207 Cipla Inc.: Regional Market Shares, 2022
Figure 208 Cipla Inc.: R&D Expense, 2018-2022 (US$ Million, AGR%)
Figure 209 Biocon: Net Revenue, 2018-2022 (US$ Million, AGR%)
Figure 210 Biocon: Segmental Market Shares, 2022
Figure 211 Biocon: R&D Expense, 2018-2022 (US$ Million, AGR%)
Figure 212 Aurobindo Pharma: Net Revenue, 2018-2022 (US$ Million, AGR%)
Figure 213 Endo International plc: Net Revenue, 2018-2022 (US$ Million, AGR%)
Figure 214 Endo International plc..: R&D Expense, 2018-2022 (US$ Million, AGR%)
Figure 215 Torrent Pharmaceuticals Ltd.: Net Revenue, 2018-2022 (US$ Million, AGR%)
Figure 216 Torrent Pharmaceuticals Ltd.: Regional Market Shares, 2022
Figure 217 Amneal Pharmaceuticals LLC: Net Revenue, 2018-2022 (US$ Million, AGR%)
Figure 218 Amneal Pharmaceuticals LLC: R&D Expense, 2018-2022 (US$ Million, AGR%)
Figure 219 Dr. Reddy’s Laboratories Ltd.: Net Revenue, 2018-2022 (US$ Million, AGR%)
Figure 220 Dr. Reddy’s Laboratories Ltd.: Regional Market Shares, 2022
Figure 221 Dr. Reddy’s Laboratories Ltd.: R&D Expense, 2018-2022 (US$ Million, AGR%)
Figure 222 Sun Pharmaceutical Industries Ltd.: Net Revenue, 2018-2022 (US$ Million, AGR%)
Figure 223 Sun Pharmaceutical Industries Ltd.: R&D Expense, 2018-2022 (US$ Million, AGR%)

ページTOPに戻る

Table of Contents
List of Tables/Graphs

Summary

Report Details

The Generic Drugs Market Report 2024-2034: This report will prove invaluable to leading firms striving for new revenue pockets if they wish to better understand the industry and its underlying dynamics. It will be useful for companies that would like to expand into different industries or to expand their existing operations in a new region.

Rising Geriatric Population and Cost Affordability of Generic Drugs Projected to Boost Industry Growth

The generic drugs market is expected to be significantly driven by key factors such as the rising geriatric population and the cost affordability and effectiveness of generic medications. As the global demographic structure shifts towards an aging population, the prevalence of chronic diseases increases, necessitating long-term treatments. Generic drugs, known for their therapeutic equivalence to brand-name counterparts and cost-effectiveness, emerge as crucial solutions to meet the healthcare needs of the elderly. The affordability of generic drugs aligns with the economic constraints often faced by seniors, fostering widespread adoption. Governments and healthcare systems, recognizing the financial advantages and accessibility benefits of generic drugs, are likely to support policies and initiatives that further propel market growth. The combination of a growing elderly population seeking affordable treatments and the proven effectiveness of generic drugs positions this market to play a pivotal role in addressing healthcare challenges and ensuring broader access to essential medications.

Adverse Effects Associated with Drugs Likely to Challenge Market Growth

Adverse effects associated with drugs are anticipated to pose a substantial challenge for the generic drugs market. While generic medications aim to replicate the therapeutic effects of their brand-name counterparts, the one-size-fits-all approach may not adequately address individual variations in patient response. This lack of individualized formulations raises concerns about potential adverse reactions, as patients may experience side effects or inadequate therapeutic responses. Variability in bioavailability among generic drugs further complicates the scenario, potentially leading to variations in drug concentration levels and subsequent adverse effects. Moreover, differences in inactive ingredients between generic and brand-name drugs may impact tolerability, especially for individuals with allergies or sensitivities, creating a need for standardized formulations. The limited post-market surveillance for generic drugs compared to brand-name counterparts raises challenges in timely identification and management of adverse effects, impacting consumer confidence. Addressing these adverse effects associated with generic drugs requires enhanced regulatory measures, rigorous quality control, and a focus on individualized medicine to ensure the sustained growth and success of the generic drugs market.

What Questions Should You Ask before Buying a Market Research Report?

How is the generic drugs market evolving?
What is driving and restraining the generic drugs market?
How will each generic drugs submarket segment grow over the forecast period and how much revenue will these submarkets account for in 2034?
How will the market shares for each generic drugs submarket develop from 2024 to 2034?
What will be the main driver for the overall market from 2024 to 2034?
Will leading generic drugs markets broadly follow the macroeconomic dynamics, or will individual national markets outperform others?
How will the market shares of the national markets change by 2034 and which geographical region will lead the market in 2034?
Who are the leading players and what are their prospects over the forecast period?
How will the industry evolve during the period between 2024 and 2034? What are the implications of generic drugs projects taking place now and over the next 10 years?
Is there a greater need for product commercialisation to further scale the generic drugs market?
Where is the generic drugs market heading and how can you ensure you are at the forefront of the market?
What are the best investment options for new product and service lines?
What are the key prospects for moving companies into a new growth path and C-suite?

You need to discover how this will impact the Generic Drugs Market today, and over the next 10 years:

Our 357-page report provides 133 tables, 223 charts/graphs exclusively to you.
The report highlights key lucrative areas in the industry so you can target them – NOW.
It contains in-depth analysis of global, regional and national sales and growth.
It highlights for you the key successful trends, changes and revenue projections made by your competitors.

This report tells you TODAY how the Generic Drugs Market will develop in the next 10 years, and in line with the variations in COVID-19 economic recession and bounce. This market is more critical now than at any point over the last 10 years.

Forecasts to 2034 and other analyses reveal commercial prospects

In addition to revenue forecasting to 2034, our new study provides you with recent results, growth rates, and market shares.
You will find original analyses, with business outlooks and developments.
Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints and challenges), cost structure, impact of rising generic drugs prices and recent developments.

This report includes data analysis and invaluable insight into how COVID-19 will affect the industry and your company. Four COVID-19 recovery patterns and their impact, namely, “V”, “L”, “W” and “U” are discussed in this report.

Segments Covered in the Report

Type

Simple Generics
Specialty Generics
Biosimilars

Route of Administration

Oral
Parenteral
Topical
Others

Indication

Central Nervous System (CNS)
Oncology
Infectious Diseases
Cardiovascular Diseases
Gastrointestinal Diseases
Musculoskeletal Diseases
Others

Drug Class

Antibiotics
Antihistamines
Analgesics
Antihypertensive
Antidiabetic
Antipyretic
Others

Prescription Type

Prescription Generics
Over-the-Counter (OTC) Generics

Distribution Channel

Retail Pharmacies
Hospital Pharmacies
Online Pharmacies
Others

In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for five regional and 20 leading national markets:

North America

U.S.
Canada

Europe

Germany
UK
France
Italy
Spain
Rest of Europe

Asia Pacific

China
Japan
India
Australia
South Korea
Rest of Asia Pacific

Latin America

Brazil
Argentina
Rest of Latin America

MEA

GCC Countries
South Africa
Rest of MEA

The report also includes profiles and for some of the leading companies in the Generic Drugs Market, 2024 to 2034, with a focus on this segment of these companies’ operations.

Leading companies and the potential for market growth

Alkem Laboratories Ltd.
Amneal Pharmaceuticals LLC
Aurobindo Pharma
Biocon
Cipla Inc.
Dr. Reddy’s Laboratories Ltd.
Endo International plc
Lupin
Novartis AG
Sun Pharmaceuticals Industries Ltd.
Teva Pharmaceutical Industries Ltd.
Torrent Pharmaceuticals Ltd.
Viatris Inc.

Overall world revenue for Generic Drugs Market, 2024 to 2034 in terms of value the market will surpass US$450.0 billion in 2024, our work calculates. We predict strong revenue growth through to 2034. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.

How will the Generic Drugs Market, 2024 to 2034 report help you?

In summary, our 350+ page report provides you with the following knowledge:

Revenue forecasts to 2034 for Generic Drugs Market, 2024 to 2034, with forecasts for type, prescription type, indication, drug class, route of administration, distribution channel, each forecast at a global and regional level – discover the industry’s prospects, finding the most lucrative places for investments and revenues.
Revenue forecasts to 2034 for five regional and 20 key national markets – See forecasts for the Generic Drugs Market, 2024 to 2034 market in North America, Europe, Asia-Pacific, Latin America and MEA. Also forecasted is the market in the US, Canada, Brazil, Germany, France, UK, Italy, China, India, Japan, and Australia among other prominent economies.
Prospects for established firms and those seeking to enter the market – including company profiles for 13 of the major companies involved in the Generic Drugs Market, 2024 to 2034.

Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with invaluable business intelligence.

Information found nowhere else

With our new report, you are less likely to fall behind in knowledge or miss out on opportunities. See how our work could benefit your research, analyses, and decisions. Visiongain’s study is for everybody needing commercial analyses for the Generic Drugs Market, 2024 to 2034, market-leading companies. You will find data, trends and predictions.

ページTOPに戻る

Table of Contents

1 Report Overview
1.1 Objectives of the Study
1.2 Introduction to Generic Drugs Market
1.3 What This Report Delivers
1.4 Why You Should Read This Report
1.5 Key Questions Answered by This Analytical Report
1.6 Who is This Report for?
1.7 Methodology
1.7.1 Market Definitions
1.7.2 Market Evaluation & Forecasting Methodology
1.7.3 Data Validation
1.7.3.1 Primary Research
1.7.3.2 Secondary Research
1.8 Frequently Asked Questions (FAQs)
1.9 Associated Visiongain Reports
1.10 About Visiongain

2 Executive Summary

3 Market Overview
3.1 Key Findings
3.2 Market Dynamics
3.2.1 Market Driving Factors
3.2.1.1 Cost Affordability and Effectiveness of Generic Drugs
3.2.1.2 Strategic Partnerships among Generic Drugs Manufacturers
3.2.1.3 Rise in Geriatric Population
3.2.1.4 Rise in Chronic Disorders
3.2.1.5 Rising Government Initiative to Promote Generic Drugs
3.2.2 Market Restraining Factors
3.2.2.1 Stringent Government Regulations
3.2.2.2 Brand Loyalty
3.2.2.3 Intellectual Property Lawsuits and Patent Disputes
3.2.2.4 Adverse Effects Associated with the Drugs
3.2.3 Market Opportunities
3.2.3.1 Patent Expiration of Blockbuster Drugs in this Decade
3.2.3.2 Growth of Biologics and Biosimilars
3.3 COVID-19 Impact Analysis
3.4 Porter’s Five Forces Analysis
3.4.1 Bargaining Power of Suppliers
3.4.2 Bargaining Power of Buyers
3.4.3 Competitive Rivalry
3.4.4 Threat from Substitutes
3.4.5 Threat of New Entrants
3.5 PEST Analysis
3.5.1 Political
3.5.2 Economical
3.5.3 Social
3.5.4 Technological

4 Generic Drugs Market Analysis by Type
4.1 Key Findings
4.2 Type Segment: Market Attractiveness Index
4.3 Generic Drugs Market Size Estimation and Forecast by Type
4.4 Simple Generics
4.4.1 Market Size by Region, 2024-2034 (US$ Billion)
4.4.2 Market Share by Region, 2024 & 2034 (%)
4.5 Specialty Generics
4.5.1 Market Size by Region, 2024-2034 (US$ Billion)
4.5.2 Market Share by Region, 2024 & 2034 (%)
4.6 Biosimilars
4.6.1 Market Size by Region, 2024-2034 (US$ Billion)
4.6.2 Market Share by Region, 2024 & 2034 (%)

5 Generic Drugs Market Analysis by Prescription Type
5.1 Key Findings
5.2 Prescription Type Segment: Market Attractiveness Index
5.4 Generic Drugs Market Size Estimation and Forecast by Prescription Type
5.5 Prescription Generics
5.5.1 Market Size by Region, 2024-2034 (US$ Billion)
5.5.2 Market Share by Region, 2024 & 2034 (%)
5.6 Over-the-Counter (OTC) Generics
5.6.1 Market Size by Region, 2024-2034 (US$ Billion)
5.6.2 Market Share by Region, 2024 & 2034 (%)

6 Generic Drugs Market Analysis by Indication
6.1 Key Findings
6.2 Indication Segment: Market Attractiveness Index
6.4 Generic Drugs Market Size Estimation and Forecast by Indication
6.5 Central Nervous System (CNS)
6.5.1 Market Size by Region, 2024-2034 (US$ Billion)
6.5.2 Market Share by Region, 2024 & 2034 (%)
6.6 Oncology
6.6.1 Market Size by Region, 2024-2034 (US$ Billion)
6.6.2 Market Share by Region, 2024 & 2034 (%)
6.7 Infectious Diseases
6.7.1 Market Size by Region, 2024-2034 (US$ Billion)
6.7.2 Market Share by Region, 2024 & 2034 (%)
6.8 Cardiovascular Diseases
6.8.1 Market Size by Region, 2024-2034 (US$ Billion)
6.8.2 Market Share by Region, 2024 & 2034 (%)
6.9 Gastrointestinal Diseases
6.9.1 Market Size by Region, 2024-2034 (US$ Billion)
6.9.2 Market Share by Region, 2024 & 2034 (%)
6.10 Musculoskeletal Diseases
6.10.1 Market Size by Region, 2024-2034 (US$ Billion)
6.10.2 Market Share by Region, 2024 & 2034 (%)
6.11 Others
6.11.1 Market Size by Region, 2024-2034 (US$ Billion)
6.11.2 Market Share by Region, 2024 & 2034 (%)

7 Generic Drugs Market Analysis by Drug Class
7.1 Key Findings
7.2 Drug Class Segment: Market Attractiveness Index
7.4 Generic Drugs Market Size Estimation and Forecast by Drug Class
7.5 Antibiotics
7.5.1 Market Size by Region, 2024-2034 (US$ Billion)
7.5.2 Market Share by Region, 2024 & 2034 (%)
7.6 Antihistamines
7.6.1 Market Size by Region, 2024-2034 (US$ Billion)
7.6.2 Market Share by Region, 2024 & 2034 (%)
7.7 Analgesics
7.7.1 Market Size by Region, 2024-2034 (US$ Billion)
7.7.2 Market Share by Region, 2024 & 2034 (%)
7.8 Antihypertensive
7.8.1 Market Size by Region, 2024-2034 (US$ Billion)
7.8.2 Market Share by Region, 2024 & 2034 (%)
7.9 Antidiabetic
7.9.1 Market Size by Region, 2024-2034 (US$ Billion)
7.9.2 Market Share by Region, 2024 & 2034 (%)
7.10 Antipyretic
7.10.1 Market Size by Region, 2024-2034 (US$ Billion)
7.10.2 Market Share by Region, 2024 & 2034 (%)
7.11 Others
7.11.1 Market Size by Region, 2024-2034 (US$ Billion)
7.11.2 Market Share by Region, 2024 & 2034 (%)

8 Generic Drugs Market Analysis by Route of Administration
8.1 Key Findings
8.2 Route of Administration Segment: Market Attractiveness Index
8.4 Generic Drugs Market Size Estimation and Forecast by Route of Administration
8.5 Oral
8.5.1 Market Size by Region, 2024-2034 (US$ Billion)
8.5.2 Market Share by Region, 2024 & 2034 (%)
8.6 Parenteral
8.6.1 Market Size by Region, 2024-2034 (US$ Billion)
8.6.2 Market Share by Region, 2024 & 2034 (%)
8.7 Topical
8.7.1 Market Size by Region, 2024-2034 (US$ Billion)
8.7.2 Market Share by Region, 2024 & 2034 (%)
8.8 Others
8.8.1 Market Size by Region, 2024-2034 (US$ Billion)
8.8.2 Market Share by Region, 2024 & 2034 (%)

9 Generic Drugs Market Analysis by Distribution Channel
9.1 Key Findings
9.2 Distribution Channel Segment: Market Attractiveness Index
9.4 Generic Drugs Market Size Estimation and Forecast by Distribution Channel
9.5 Hospital Pharmacies
9.5.1 Market Size by Region, 2024-2034 (US$ Billion)
9.5.2 Market Share by Region, 2024 & 2034 (%)
9.6 Retail Pharmacies
9.6.1 Market Size by Region, 2024-2034 (US$ Billion)
9.6.2 Market Share by Region, 2024 & 2034 (%)
9.7 Online Pharmacies
9.7.1 Market Size by Region, 2024-2034 (US$ Billion)
9.7.2 Market Share by Region, 2024 & 2034 (%)
9.8 Others
9.8.1 Market Size by Region, 2024-2034 (US$ Billion)
9.8.2 Market Share by Region, 2024 & 2034 (%)

10 Generic Drugs Market Analysis by Region
10.1 Key Findings
10.3 Regional Market Size Estimation and Forecast

11 North America Generic Drugs Market Analysis
11.1 Key Findings
11.2 North America Generic Drugs Market Attractiveness Index
11.3 North America Generic Drugs Market by Country, 2024, 2029 & 2034 (US$ Billion)
11.4 North America Generic Drugs Market Size Estimation and Forecast by Country
11.5 North America Generic Drugs Market Size Estimation and Forecast by Type
11.6 North America Generic Drugs Market Size Estimation and Forecast by Route of Administration
11.7 North America Generic Drugs Market Size Estimation and Forecast by Indication
11.8 North America Generic Drugs Market Size Estimation and Forecast by Drug Class
11.9 North America Generic Drugs Market Size Estimation and Forecast by Prescription Type
11.10 North America Generic Drugs Market Size Estimation and Forecast by Distribution Channel
11.11 U.S. Generic Drugs Market Analysis
11.12 Canada Generic Drugs Market Analysis

12 Europe Generic Drugs Market Analysis
12.1 Key Findings
12.2 Europe Generic Drugs Market Attractiveness Index
12.3 Europe Generic Drugs Market by Country, 2024, 2029 & 2034 (US$ Billion)
12.4 Europe Generic Drugs Market Size Estimation and Forecast by Country
12.5 Europe Generic Drugs Market Size Estimation and Forecast by Type
12.6 Europe Generic Drugs Market Size Estimation and Forecast by Route of Administration
12.7 Europe Generic Drugs Market Size Estimation and Forecast by Indication
12.8 Europe Generic Drugs Market Size Estimation and Forecast by Drug Class
12.9 Europe Generic Drugs Market Size Estimation and Forecast by Prescription Type
12.10 Europe Generic Drugs Market Size Estimation and Forecast by Distribution Channel
12.11 Germany Generic Drugs Market Analysis
12.12 UK Generic Drugs Market Analysis
12.13 France Generic Drugs Market Analysis
12.14 Italy Generic Drugs Market Analysis
12.15 Spain Generic Drugs Market Analysis
12.16 Rest of Europe Generic Drugs Market Analysis

13 Asia Pacific Generic Drugs Market Analysis
13.1 Key Findings
13.2 Asia Pacific Generic Drugs Market Attractiveness Index
13.3 Asia Pacific Generic Drugs Market by Country, 2024, 2029 & 2034 (US$ Billion)
13.4 Asia Pacific Generic Drugs Market Size Estimation and Forecast by Country
13.5 Asia Pacific Generic Drugs Market Size Estimation and Forecast by Type
13.6 Asia Pacific Generic Drugs Market Size Estimation and Forecast by Route of Administration
13.7 Asia Pacific Generic Drugs Market Size Estimation and Forecast by Indication
13.8 Asia Pacific Generic Drugs Market Size Estimation and Forecast by Drug Class
13.9 Asia Pacific Generic Drugs Market Size Estimation and Forecast by Prescription Type
13.10 Asia Pacific Generic Drugs Market Size Estimation and Forecast by Distribution Channel
13.11 Japan Generic Drugs Market Analysis
13.12 China Generic Drugs Market Analysis
13.13 India Generic Drugs Market Analysis
13.14 Australia Generic Drugs Market Analysis
13.15 South Korea Generic Drugs Market Analysis
13.16 Rest of Asia Pacific Generic Drugs Market Analysis

14 Latin America Generic Drugs Market Analysis
14.1 Key Findings
14.2 Latin America Generic Drugs Market Attractiveness Index
14.3 Latin America Generic Drugs Market by Country, 2024, 2029 & 2034 (US$ Billion)
14.4 Latin America Generic Drugs Market Size Estimation and Forecast by Country
14.5 Latin America Generic Drugs Market Size Estimation and Forecast by Type
14.6 Latin America Generic Drugs Market Size Estimation and Forecast by Route of Administration
14.7 Latin America Generic Drugs Market Size Estimation and Forecast by Indication
14.8 Latin America Generic Drugs Market Size Estimation and Forecast by Drug Class
14.9 Latin America Generic Drugs Market Size Estimation and Forecast by Prescription Type
14.10 Latin America Generic Drugs Market Size Estimation and Forecast by Distribution Channel
14.11 Brazil Generic Drugs Market Analysis
14.12 Argentina Generic Drugs Market Analysis
14.13 Rest of Latin America Generic Drugs Market Analysis

15 MEA Generic Drugs Market Analysis
15.1 Key Findings
15.2 MEA Generic Drugs Market Attractiveness Index
15.3 MEA Generic Drugs Market by Country, 2024, 2029 & 2034 (US$ Billion)
15.4 MEA Generic Drugs Market Size Estimation and Forecast by Country
15.5 MEA Generic Drugs Market Size Estimation and Forecast by Type
15.6 MEA Generic Drugs Market Size Estimation and Forecast by Route of Administration
15.7 MEA Generic Drugs Market Size Estimation and Forecast by Indication
15.8 MEA Generic Drugs Market Size Estimation and Forecast by Drug Class
15.9 MEA Generic Drugs Market Size Estimation and Forecast by Prescription Type
15.10 MEA Generic Drugs Market Size Estimation and Forecast by Distribution Channel
15.11 GCC Generic Drugs Market Analysis
15.12 South Africa Generic Drugs Market Analysis
15.13 Rest of MEA Generic Drugs Market Analysis

16 Company Profiles
16.1 Competitive Landscape, 2023
16.2 Novartis AG
16.2.1 Company Snapshot
16.2.2 Company Overview
16.2.3 Financial Analysis
16.2.3.1 Net Revenue, 2018-2022
16.2.3.2 Regional Market Shares, 2022
16.2.3.3 R&D Expense, 2018-2022
16.2.5 Product Benchmarking
16.2.6 Strategic Outlook
16.3 Teva Pharmaceutical Industries Ltd.
16.3.1 Company Snapshot
16.3.2 Company Overview
16.3.3 Financial Analysis
16.3.3.1 Revenue, 2018-2022
16.3.3.2 Regional Market Shares, 2022
16.3.3.3 R&D Expense, 2018-2022
16.3.5 Product Benchmarking
16.3.6 Strategic Outlook
16.4 Viatris Inc.
16.4.1 Company Snapshot
16.4.2 Company Overview
16.4.3 Financial Analysis
16.4.3.1 Revenue, 2018-2022
16.4.3.2 Regional Market Shares, 2022
16.4.3.3 R&D Expense, 2018-2022
16.4.5 Product Benchmarking
16.4.6 Strategic Outlook
16.5 Lupin
16.5.1 Company Snapshot
16.5.2 Company Overview
16.5.3 Financial Analysis
16.5.3.1 Revenue, 2018-2022
16.5.3.2 R&D Expense, 2018-2022
16.5.5 Product Benchmarking
16.5.6 Strategic Outlook
16.6 Alkem Laboratories Ltd.
16.6.1 Company Snapshot
16.6.2 Company Overview
16.6.3 Financial Analysis
16.6.3.1 Net Revenue, 2018-2022
16.6.3.2 Regional Market Shares, 2022
16.6.3.3 R&D Expense, 2018-2022
16.6.4 Product Benchmarking
16.6.5 Strategic Outlook
16.7 Cipla Inc.
16.7.1 Company Snapshot
16.7.2 Company Overview
16.7.3 Financial Analysis
16.7.3.1 Revenue, 2018-2022
16.7.3.2 Regional Market Shares, 2022
16.7.3.3 R&D Expense, 2018-2022
16.7.5 Product Benchmarking
16.7.6 Strategic Outlook
16.8 Biocon
16.8.1 Company Snapshot
16.8.2 Company Overview
16.8.3 Financial Analysis
16.8.3.1 Revenue, 2018-2022
16.8.3.2 Segmental Market Shares, 2022
16.8.3.3 R&D Expense, 2018-2022
16.8.5 Product Benchmarking
16.8.6 Strategic Outlook
16.9 Aurobindo Pharma
16.9.1 Company Snapshot
16.9.2 Company Overview
16.9.3 Financial Analysis
16.9.3.1 Revenue, 2018-2022
16.9.4 Product Benchmarking
16.9.5 Strategic Outlook
16.10 Endo International plc
16.10.1 Company Snapshot
16.10.2 Company Overview
16.10.3 Financial Analysis
16.10.3.1 Revenue, 2018-2022
16.10.3.2 R&D Expense, 2018-2022
16.10.4 Product Benchmarking
16.10.5 Strategic Outlook
16.11 Torrent Pharmaceuticals Ltd.
16.11.1 Company Snapshot
16.11.2 Company Overview
16.11.3 Financial Analysis
16.11.3.1 Revenue, 2018-2022
16.11.3.2 Regional Market Shares, 2022
16.11.4 Product Benchmarking
16.12 Amneal Pharmaceuticals LLC
16.12.1 Company Snapshot
16.12.2 Company Overview
16.12.3 Financial Analysis
16.12.3.1 Revenue, 2018-2022
16.12.3.2 R&D Expense, 2018-2022
16.12.4 Product Benchmarking
16.12.5 Strategic Outlook
16.13 Dr. Reddy’s Laboratories Ltd.
16.13.1 Company Snapshot
16.13.2 Company Overview
16.13.3 Financial Analysis
16.13.3.1 Revenue, 2018-2022
16.13.3.2 Regional Market Shares, 2022
16.13.3.3 R&D Expense, 2018-2022
16.13.4 Product Benchmarking
16.13.5 Strategic Outlook
16.14 Sun Pharmaceutical Industries Ltd.
16.14.1 Company Snapshot
16.14.2 Company Overview
16.14.3 Financial Analysis
16.14.3.1 Revenue, 2018-2022
16.14.3.2 R&D Expense, 2018-2022
16.14.4 Product Benchmarking
16.14.5 Strategic Outlook

17 Conclusion and Recommendations
17.1 Concluding Remarks from Visiongain
17.2 Recommendations for Market Players

ページTOPに戻る

List of Tables/Graphs

List of Tables
Table 1 Generic Drugs Market Snapshot, 2024 & 2034 (US$ billion, CAGR %)
Table 2 Patent Expiration
Table 3 Global Generic Drugs Market Forecast by Region 2024-2034 (US$ Billion, AGR%, CAGR%): "V" Shaped Recovery
Table 4 Generic Drugs Market Forecast by Region 2024-2034 (US$ Billion, AGR%, CAGR%): "U" Shaped Recovery
Table 5 Global Generic Drugs Market Forecast by Region 2024-2034 (US$ Billion, AGR%, CAGR%): "W" Shaped Recovery
Table 6 Global Generic Drugs Market Forecast by Region 2024-2034 (US$ Billion, AGR%, CAGR%): "L" Shaped Recovery
Table 7 Generic Drugs Market Forecast by Type, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 8 Simple Generics Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 9 Specialty Generics Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 10 Biosimilars Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 11 Generic Drugs Market Forecast by Type, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 12 Prescription Generics Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 13 Over-the-Counter (OTC) Generics Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 14 Generic Drugs Market Forecast by Indication, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 15 Central Nervous System (CNS) Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 16 Oncology Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 17 Infectious Diseases Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 18 Cardiovascular Diseases Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 19 Gastrointestinal Diseases Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 20 Musculoskeletal Diseases Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 21 Others Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 22 Generic Drugs Market Forecast by Drug Class, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 23 Antibiotics Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 24 Antihistamines Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 25 Analgesics Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 26 Antihypertensive Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 27 Antidiabetic Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 28 Antipyretic Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 29 Others Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 30 Generic Drugs Market Forecast by Route of Administration, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 31 Oral Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 32 Parenteral Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 33 Topical Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 34 Others Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 35 Generic Drugs Market Forecast by Distribution Channel, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 36 Hospital Pharmacies Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 37 Retail Pharmacies Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 38 Online Pharmacies Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 39 Others Segment Market Forecast by Region, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 40 Global Generic drugs Market Forecast by Region 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 41 North America Generic Drugs Market Forecast by Country, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 42 North America Generic Drugs Market Forecast by Type, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 43 North America Generic Drugs Market Forecast by Route of Administration, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 44 North America Generic Drugs Market Forecast by Indication, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 45 North America Generic Drugs Market Forecast by Drug Class, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 46 North America Generic drugs Market Forecast by Prescription Type, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 47 North America Generic Drugs Market Forecast by Distribution Channel, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 48 U.S. Generic Drugs Market Forecast by Country, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 49 Canada Generic Drugs Market Forecast by Country, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 50 Europe Generic Drugs Market Forecast by Country, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 51 Europe Generic Drugs Market Forecast by Type, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 52 Europe Generic Drugs Market Forecast by Route of Administration, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 53 Europe Generic Drugs Market Forecast by Indication, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 54 Europe Generic Drugs Market Forecast by Drug Class, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 55 Europe Generic drugs Market Forecast by Prescription Type, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 56 Europe Generic Drugs Market Forecast by Distribution Channel, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 57 Germany Generic Drugs Market Forecast by Country, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 58 UK Generic Drugs Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 59 France Generic Drugs Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 60 Italy Generic Drugs Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 61 Spain Generic Drugs Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 62 Rest of Europe Generic Drugs Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 63 Asia Pacific Generic Drugs Market Forecast by Country, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 64 Asia Pacific Generic Drugs Market Forecast by Type, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 65 Asia Pacific Generic Drugs Market Forecast by Route of Administration, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 66 Asia Pacific Generic Drugs Market Forecast by Indication, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 67 Asia Pacific Generic Drugs Market Forecast by Drug Class, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 68 Asia Pacific Generic drugs Market Forecast by Prescription Type, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 69 Asia Pacific Generic Drugs Market Forecast by Distribution Channel, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 70 Japan Generic Drugs Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 71 China Generic Drugs Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 72 India Generic Drugs Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 73 Australia Generic Drugs Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 74 South Korea Generic Drugs Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 75 Rest of Asia-Pacific Generic Drugs Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 76 Latin America Generic Drugs Market Forecast by Country, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 77 Latin America Generic Drugs Market Forecast by Type, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 78 Latin America Generic Drugs Market Forecast by Route of Administration, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 79 Latin America Generic Drugs Market Forecast by Indication, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 80 Latin America Generic Drugs Market Forecast by Drug Class, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 81 Latin America Generic drugs Market Forecast by Prescription Type, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 82 Latin America Generic Drugs Market Forecast by Distribution Channel, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 83 Brazil Generic Drugs Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 84 Argentina Generic Drugs Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 85 Rest of Latin America Generic Drugs Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 86 MEA Generic Drugs Market Forecast by Country, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 87 MEA Generic Drugs Market Forecast by Type, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 88 MEA Generic Drugs Market Forecast by Route of Administration, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 89 MEA Generic Drugs Market Forecast by Indication, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 90 MEA Generic Drugs Market Forecast by Drug Class, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 91 MEA Generic drugs Market Forecast by Prescription Type, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 92 MEA Generic Drugs Market Forecast by Distribution Channel, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 93 GCC Generic Drugs Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 94 South Africa Generic Drugs Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 95 Rest of MEA Generic Drugs Market Forecast, 2024-2034 (US$ Billion, AGR%, CAGR%)
Table 96 Novartis AG: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 97 Novartis AG: Product Benchmarking
Table 98 Novartis AG: Strategic Outlook
Table 99 Teva Pharmaceutical Industries Ltd.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 100 Teva Pharmaceutical Industries Ltd.: Product Benchmarking
Table 101 Teva Pharmaceutical Industries Ltd.: Strategic Outlook
Table 102 Viatris Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 103 Viatris Inc.: Product Benchmarking
Table 104 Viatris Inc.: Strategic Outlook
Table 105 Lupin: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 106 Lupin: Product Benchmarking
Table 107 Lupin: Strategic Outlook
Table 108 Alkem Laboratories Ltd.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 109 Alkem Laboratories Ltd.: Product Benchmarking
Table 110 Alkem Laboratories Ltd.: Strategic Outlook
Table 111 Cipla Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 112 Cipla Inc.: Product Benchmarking
Table 113 Cipla Inc.: Strategic Outlook
Table 114 Biocon: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 115 Biocon: Product Benchmarking
Table 116 Biocon: Strategic Outlook
Table 117 Aurobindo Pharma: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 118 Aurobindo Pharma: Product Benchmarking
Table 119 Aurobindo Pharma: Strategic Outlook
Table 120 Endo International plc: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 121 Endo International plc: Product Benchmarking
Table 122 Endo International plc: Strategic Outlook
Table 123 Torrent Pharmaceuticals Ltd.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 124 Torrent Pharmaceuticals Ltd.: Product Benchmarking
Table 125 Amneal Pharmaceuticals LLC: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 126 Amneal Pharmaceuticals LLC: Product Benchmarking
Table 127 Amneal Pharmaceuticals LLC: Strategic Outlook
Table 128 Dr. Reddy’s Laboratories Ltd.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 129 Dr. Reddy’s Laboratories Ltd.: Product Benchmarking
Table 130 Dr. Reddy’s Laboratories Ltd.: Strategic Outlook
Table 131 Sun Pharmaceutical Industries Ltd.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 132 Sun Pharmaceutical Industries Ltd.: Product Benchmarking
Table 133 Sun Pharmaceutical Industries Ltd.: Strategic Outlook

List of Figures
Figure 1 Generic Drugs Market Segmentation
Figure 2 Generic Drugs Market by Type: Market Attractiveness Index
Figure 3 Generic Drugs Market Forecast by Route of Administration: Market Attractiveness Index
Figure 4 Generic Drugs Market Forecast by Indication: Market Attractiveness Index
Figure 5 Generic Drugs Market Forecast by Indication: Market Attractiveness Index
Figure 6 Generic Drugs Market Forecast by Prescription Type: Market Attractiveness Index
Figure 7 Generic Drugs Market Forecast by Distribution Channel: Market Attractiveness Index
Figure 8 Generic Drugs Market Attractiveness Index by Region
Figure 9 Global Generic Drugs Market: Market Dynamics
Figure 10 Generic Drugs Market by Region, 2024-2034 (US$ Billion, AGR (%), CAGR (%)): “V” Shaped Recovery
Figure 11 Generic Drugs Market by Region, 2024-2034 (US$ Billion, AGR (%), CAGR (%)): “U” Shaped Recovery
Figure 12 Generic Drugs Market by Region, 2024-2034 (US$ Billion, AGR (%), CAGR (%)): “W” Shaped Recovery
Figure 13 Generic Drugs Market by Region, 2024-2034 (US$ Billion, AGR (%), CAGR (%)): “L” Shaped Recovery
Figure 14 Generic drugs Market: Porter’s Five Forces Analysis
Figure 15 Generic Drugs Market: PEST Analysis
Figure 16 Generic Drugs Market Forecast by Type: Market Attractiveness Index
Figure 17 Generic Drugs Market Forecast by Type, 2024-2034 (US$ Billion)
Figure 18 Generic Drugs Market Share Forecast by Type, 2024, 2029, 2034 (%)
Figure 19 Simple Generics Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
Figure 20 Simple Generics Market Share Forecast by Region, 2024 & 2034 (%)
Figure 21 Specialty Generics Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
Figure 22 Specialty Generics Market Share Forecast by Region, 2024 & 2034 (%)
Figure 23 Biosimilars Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
Figure 24 Biosimilars Market Share Forecast by Region, 2024 & 2034 (%)
Figure 25 Generic Drugs Market Forecast by Prescription Type: Market Attractiveness Index
Figure 26 Generic Drugs Market Forecast By Prescription Type, 2024-2034 (US$ Billion, AGR %)
Figure 27 Generic Drugs Market Share Forecast by Prescription Type, 2024, 2029, 2034 (%)
Figure 28 Prescription Generics Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
Figure 29 Prescription Generics Market Share Forecast by Region, 2024 & 2034 (%)
Figure 30 Over-the-Counter (OTC) Generics Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
Figure 31 Over-the-Counter (OTC) Generics Market Share Forecast by Region, 2024 & 2034 (%)
Figure 32 Generic Drugs Market Forecast by Indication: Market Attractiveness Index
Figure 33 Generic Drugs Market Forecast By Indication, 2024-2034 (US$ Billion, AGR %)
Figure 34 Generic Drugs Market Share Forecast by Indication, 2024, 2029, 2034 (%)
Figure 35 Central Nervous System (CNS) Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
Figure 36 Central Nervous System (CNS) Market Share Forecast by Region, 2024 & 2034 (%)
Figure 37 Oncology Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
Figure 38 Oncology Market Share Forecast by Region, 2024 & 2034 (%)
Figure 39 Infectious Diseases Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
Figure 40 Infectious Diseases Market Share Forecast by Region, 2024 & 2034 (%)
Figure 41 Cardiovascular Diseases Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
Figure 42 Cardiovascular Diseases Market Share Forecast by Region, 2024 & 2034 (%)
Figure 43 Gastrointestinal Diseases Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
Figure 44 Gastrointestinal Diseases Market Share Forecast by Region, 2024 & 2034 (%)
Figure 45 Musculoskeletal Diseases Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
Figure 46 Musculoskeletal Diseases Market Share Forecast by Region, 2024 & 2034 (%)
Figure 47 Others Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
Figure 48 Others Market Share Forecast by Region, 2024 & 2034 (%)
Figure 49 Generic Drugs Market Forecast by Drug Class: Market Attractiveness Index
Figure 50 Generic Drugs Market Forecast By Drug Class, 2024-2034 (US$ Billion, AGR %)
Figure 51 Generic Drugs Market Share Forecast by Drug Class, 2024, 2029, 2034 (%)
Figure 52 Antibiotics Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
Figure 53 Antibiotics Market Share Forecast by Region, 2024 & 2034 (%)
Figure 54 Antihistamines Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
Figure 55 Antihistamines Market Share Forecast by Region, 2024 & 2034 (%)
Figure 56 Analgesics Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
Figure 57 Analgesics Market Share Forecast by Region, 2024 & 2034 (%)
Figure 58 Antihypertensive Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
Figure 59 Antihypertensive Market Share Forecast by Region, 2024 & 2034 (%)
Figure 60 Antidiabetic Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
Figure 61 Antidiabetic Market Share Forecast by Region, 2024 & 2034 (%)
Figure 62 Antipyretic Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
Figure 63 Antipyretic Market Share Forecast by Region, 2024 & 2034 (%)
Figure 64 Others Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
Figure 65 Others Market Share Forecast by Region, 2024 & 2034 (%)
Figure 66 Generic Drugs Market Forecast by Route of Administration: Market Attractiveness Index
Figure 67 Generic Drugs Market Forecast By Route of Administration, 2024-2034 (US$ Billion, AGR %)
Figure 68 Generic Drugs Market Share Forecast by Route of Administration, 2024, 2029, 2034 (%)
Figure 69 Oral Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
Figure 70 Oral Market Share Forecast by Region, 2024 & 2034 (%)
Figure 71 Parenteral Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
Figure 72 Parenteral Market Share Forecast by Region, 2024 & 2034 (%)
Figure 73 Topical Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
Figure 74 Topical Market Share Forecast by Region, 2024 & 2034 (%)
Figure 75 Others Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
Figure 76 Others Market Share Forecast by Region, 2024 & 2034 (%)
Figure 77 Generic Drugs Market Forecast by Distribution Channel: Market Attractiveness Index
Figure 78 Generic Drugs Market Forecast By Distribution Channel, 2024-2034 (US$ Billion, AGR %)
Figure 79 Generic Drugs Market Share Forecast by Distribution Channel, 2024, 2029, 2034 (%)
Figure 80 Hospital Pharmacies Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
Figure 81 Hospital Pharmacies Market Share Forecast by Region, 2024 & 2034 (%)
Figure 82 Retail Pharmacies Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
Figure 83 Retail Pharmacies Market Share Forecast by Region, 2024 & 2034 (%)
Figure 84 Online Pharmacies Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
Figure 85 Online Pharmacies Market Share Forecast by Region, 2024 & 2034 (%)
Figure 86 Others Market Forecast by Region, 2024-2034 (US$ Billion, AGR %)
Figure 87 Others Market Share Forecast by Region, 2024 & 2034 (%)
Figure 88 Generic Drugs Market Forecast by Region, 2024 & 2034 (Revenue, CAGR%)
Figure 89 Generic Drugs Market Share Forecast by Region 2024, 2029, 2034(%)
Figure 90 Generic Drugs Market by Region, 2024-2034 (US$ Billion, AGR (%), CAGR (%))
Figure 91 North America Generic Drugs Market Attractiveness Index
Figure 92 North America Generic Drugs Market by Region, 2024, 2029 & 2034 (US$ Billion)
Figure 93 North America Generic Drugs Market Forecast by Country, 2024-2034 (US$ Billion, AGR %)
Figure 94 North America Generic Drugs Market Share Forecast by Country, 2024 & 2034 (%)
Figure 95 North America Generic Drugs Market Forecast by Type, 2024-2034 (US$ Billion, AGR %)
Figure 96 North America Generic Drugs Market Share Forecast by Type, 2024 & 2034 (%)
Figure 97 North America Generic Drugs Market Forecast by Route of Administration, 2024-2034 (US$ Billion, AGR %)
Figure 98 North America Generic Drugs Market Share Forecast by Route of Administration, 2024 & 2034 (%)
Figure 99 North America Generic Drugs Market Forecast by Indication, 2024-2034 (US$ Billion, AGR %)
Figure 100 North America Generic Drugs Market Share Forecast by Indication, 2024 & 2034 (%)
Figure 101 North America Generic Drugs Market Forecast by Drug Class, 2024-2034 (US$ Billion, AGR %)
Figure 102 North America Generic Drugs Market Share Forecast by Drug Class, 2024 & 2034 (%)
Figure 103 North America Generic Drugs Market Forecast by Prescription Type, 2024-2034 (US$ Billion, AGR %)
Figure 104 North America Generic Drugs Market Share Forecast by Prescription Type, 2024 & 2034 (%)
Figure 105 North America Generic Drugs Market Forecast by Distribution Channel, 2024-2034 (US$ Billion, AGR %)
Figure 106 North America Generic Drugs Market Share Forecast by Distribution Channel, 2024 & 2034 (%)
Figure 107 U.S. Generic Drugs Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 108 Canada Generic Drugs Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 109 Europe Generic Drugs Market Attractiveness Index
Figure 110 Europe Generic Drugs Market by Region, 2024, 2029 & 2034 (US$ Billion)
Figure 111 Europe Generic Drugs Market Forecast by Country, 2024-2034 (US$ Billion, AGR %)
Figure 112 Europe Generic Drugs Market Share Forecast by Country, 2024 & 2034 (%)
Figure 113 Europe Generic Drugs Market Forecast by Type, 2024-2034 (US$ Billion, AGR %)
Figure 114 Europe Generic Drugs Market Share Forecast by Type, 2024 & 2034 (%)
Figure 115 Europe Generic Drugs Market Forecast by Route of Administration, 2024-2034 (US$ Billion, AGR %)
Figure 116 Europe Generic Drugs Market Share Forecast by Route of Administration, 2024 & 2034 (%)
Figure 117 Europe Generic Drugs Market Forecast by Indication, 2024-2034 (US$ Billion, AGR %)
Figure 118 Europe Generic Drugs Market Share Forecast by Indication, 2024 & 2034 (%)
Figure 119 Europe Generic Drugs Market Forecast by Drug Class, 2024-2034 (US$ Billion, AGR %)
Figure 120 Europe Generic Drugs Market Share Forecast by Drug Class, 2024 & 2034 (%)
Figure 121 Europe Generic Drugs Market Forecast by Prescription Type, 2024-2034 (US$ Billion, AGR %)
Figure 122 Europe Generic Drugs Market Share Forecast by Prescription Type, 2024 & 2034 (%)
Figure 123 Europe Generic Drugs Market Forecast by Distribution Channel, 2024-2034 (US$ Billion, AGR %)
Figure 124 Europe Generic Drugs Market Share Forecast by Distribution Channel, 2024 & 2034 (%)
Figure 125 Germany Generic Drugs Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 126 U.K. Generic Drugs Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 127 France Generic Drugs Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 128 Italy Generic Drugs Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 129 Spain Generic Drugs Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 130 Rest of Europe Generic Drugs Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 131 Asia Pacific Generic Drugs Market Attractiveness Index
Figure 132 Asia Pacific Generic Drugs Market by Region, 2024, 2029 & 2034 (US$ Billion)
Figure 133 Asia Pacific Generic Drugs Market Forecast by Country, 2024-2034 (US$ Billion, AGR %)
Figure 134 Asia Pacific Generic Drugs Market Share Forecast by Country, 2024 & 2034 (%)
Figure 135 Asia Pacific Generic Drugs Market Forecast by Type, 2024-2034 (US$ Billion, AGR %)
Figure 136 Asia Pacific Generic Drugs Market Share Forecast by Type, 2024 & 2034 (%)
Figure 137 Asia Pacific Generic Drugs Market Forecast by Route of Administration, 2024-2034 (US$ Billion, AGR %)
Figure 138 Asia Pacific Generic Drugs Market Share Forecast by Route of Administration, 2024 & 2034 (%)
Figure 139 Asia Pacific Generic Drugs Market Forecast by Indication, 2024-2034 (US$ Billion, AGR %)
Figure 140 Asia Pacific Generic Drugs Market Share Forecast by Indication, 2024 & 2034 (%)
Figure 141 Asia Pacific Generic Drugs Market Forecast by Drug Class, 2024-2034 (US$ Billion, AGR %)
Figure 142 Asia Pacific Generic Drugs Market Share Forecast by Drug Class, 2024 & 2034 (%)
Figure 143 Asia Pacific Generic Drugs Market Forecast by Prescription Type, 2024-2034 (US$ Billion, AGR %)
Figure 144 Asia Pacific Generic Drugs Market Share Forecast by Prescription Type, 2024 & 2034 (%)
Figure 145 Asia Pacific Generic Drugs Market Forecast by Distribution Channel, 2024-2034 (US$ Billion, AGR %)
Figure 146 Asia Pacific Generic Drugs Market Share Forecast by Distribution Channel, 2024 & 2034 (%)
Figure 147 Japan Generic Drugs Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 148 China Generic Drugs Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 149 India Generic Drugs Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 150 Australia Generic Drugs Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 151 South Korea Generic Drugs Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 152 Rest of Asia Pacific Generic Drugs Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 153 Latin America Generic Drugs Market Attractiveness Index
Figure 154 Latin America Generic Drugs Market by Region, 2024, 2029 & 2034 (US$ Billion)
Figure 155 Latin America Generic Drugs Market Forecast by Country, 2024-2034 (US$ Billion, AGR %)
Figure 156 Latin America Generic Drugs Market Share Forecast by Country, 2024 & 2034 (%)
Figure 157 Latin America Generic Drugs Market Forecast by Type, 2024-2034 (US$ Billion, AGR %)
Figure 158 Latin America Generic Drugs Market Share Forecast by Type, 2024 & 2034 (%)
Figure 159 Latin America Generic Drugs Market Forecast by Route of Administration, 2024-2034 (US$ Billion, AGR %)
Figure 160 Latin America Generic Drugs Market Share Forecast by Route of Administration, 2024 & 2034 (%)
Figure 161 Latin America Generic Drugs Market Forecast by Indication, 2024-2034 (US$ Billion, AGR %)
Figure 162 Latin America Generic Drugs Market Share Forecast by Indication, 2024 & 2034 (%)
Figure 163 Latin America Generic Drugs Market Forecast by Drug Class, 2024-2034 (US$ Billion, AGR %)
Figure 164 Latin America Generic Drugs Market Share Forecast by Drug Class, 2024 & 2034 (%)
Figure 165 Latin America Generic Drugs Market Forecast by Prescription Type, 2024-2034 (US$ Billion, AGR %)
Figure 166 Latin America Generic Drugs Market Share Forecast by Prescription Type, 2024 & 2034 (%)
Figure 167 Latin America Generic Drugs Market Forecast by Distribution Channel, 2024-2034 (US$ Billion, AGR %)
Figure 168 Latin America Generic Drugs Market Share Forecast by Distribution Channel, 2024 & 2034 (%)
Figure 169 Brazil Generic Drugs Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 170 Argentina Generic Drugs Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 171 Rest of Latin America Generic Drugs Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 172 MEA Generic Drugs Market Attractiveness Index
Figure 173 MEA Generic Drugs Market by Region, 2024, 2029 & 2034 (US$ Billion)
Figure 174 MEA Generic Drugs Market Forecast by Country, 2024-2034 (US$ Billion, AGR %)
Figure 175 MEA Generic Drugs Market Share Forecast by Country, 2024 & 2034 (%)
Figure 176 MEA Generic Drugs Market Forecast by Type, 2024-2034 (US$ Billion, AGR %)
Figure 177 MEA Generic Drugs Market Share Forecast by Type, 2024 & 2034 (%)
Figure 178 MEA Generic Drugs Market Forecast by Route of Administration, 2024-2034 (US$ Billion, AGR %)
Figure 179 MEA Generic Drugs Market Share Forecast by Route of Administration, 2024 & 2034 (%)
Figure 180 MEA Generic Drugs Market Forecast by Indication, 2024-2034 (US$ Billion, AGR %)
Figure 181 MEA Generic Drugs Market Share Forecast by Indication, 2024 & 2034 (%)
Figure 182 MEA Generic Drugs Market Forecast by Drug Class, 2024-2034 (US$ Billion, AGR %)
Figure 183 MEA Generic Drugs Market Share Forecast by Drug Class, 2024 & 2034 (%)
Figure 184 MEA Generic Drugs Market Forecast by Prescription Type, 2024-2034 (US$ Billion, AGR %)
Figure 185 MEA Generic Drugs Market Share Forecast by Prescription Type, 2024 & 2034 (%)
Figure 186 MEA Generic Drugs Market Forecast by Distribution Channel, 2024-2034 (US$ Billion, AGR %)
Figure 187 MEA Generic Drugs Market Share Forecast by Distribution Channel, 2024 & 2034 (%)
Figure 188 GCC Generic Drugs Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 189 South Africa Generic Drugs Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 190 Rest of MEA Generic Drugs Market Forecast, 2024-2034 (US$ Billion, AGR %)
Figure 191 Generic Drugs Market: Company Share Analysis, 2023
Figure 192 Novartis AG: Net Revenue, 2018-2022 (US$ Million, AGR%)
Figure 193 Novartis AG: Regional Market Shares, 2022
Figure 194 Novartis AG: R&D Expense, 2018-2022 (US$ Million, AGR%)
Figure 195 Teva Pharmaceutical Industries Ltd.: Annual Revenue, 2018-2022 (US$ million, AGR%)
Figure 196 Teva Pharmaceutical Industries Ltd: Regional Market Shares, 2022
Figure 197 Teva Pharmaceutical Industries Ltd.: R&D Expense, 2018-2022 (US$ Million, AGR%)
Figure 198 Viatris Inc.: Annual Revenue, 2018-2022 (US$ Million, AGR%)
Figure 199 Viatris Inc.: Regional Market Shares, 2022
Figure 200 Viatris Inc.: R&D Expense, 2018-2022 (US$ Million, AGR%)
Figure 201 Lupin: Net Revenue, 2018-2022 (US$ Million, AGR%)
Figure 202 Lupin: R&D Expense, 2018-2022 (US$ Million, AGR%)
Figure 203 Alkem Laboratories Ltd.: Net Revenue, 2018-2022 (US$ Million, AGR%)
Figure 204 Alkem Laboratories Ltd.: Regional Market Shares, 2022
Figure 205 Alkem Laboratories Ltd.: R&D Expense, 2018-2022 (US$ Million, AGR%)
Figure 206 Cipla Inc.: Net Revenue, 2018-2022 (US$ Million, AGR%)
Figure 207 Cipla Inc.: Regional Market Shares, 2022
Figure 208 Cipla Inc.: R&D Expense, 2018-2022 (US$ Million, AGR%)
Figure 209 Biocon: Net Revenue, 2018-2022 (US$ Million, AGR%)
Figure 210 Biocon: Segmental Market Shares, 2022
Figure 211 Biocon: R&D Expense, 2018-2022 (US$ Million, AGR%)
Figure 212 Aurobindo Pharma: Net Revenue, 2018-2022 (US$ Million, AGR%)
Figure 213 Endo International plc: Net Revenue, 2018-2022 (US$ Million, AGR%)
Figure 214 Endo International plc..: R&D Expense, 2018-2022 (US$ Million, AGR%)
Figure 215 Torrent Pharmaceuticals Ltd.: Net Revenue, 2018-2022 (US$ Million, AGR%)
Figure 216 Torrent Pharmaceuticals Ltd.: Regional Market Shares, 2022
Figure 217 Amneal Pharmaceuticals LLC: Net Revenue, 2018-2022 (US$ Million, AGR%)
Figure 218 Amneal Pharmaceuticals LLC: R&D Expense, 2018-2022 (US$ Million, AGR%)
Figure 219 Dr. Reddy’s Laboratories Ltd.: Net Revenue, 2018-2022 (US$ Million, AGR%)
Figure 220 Dr. Reddy’s Laboratories Ltd.: Regional Market Shares, 2022
Figure 221 Dr. Reddy’s Laboratories Ltd.: R&D Expense, 2018-2022 (US$ Million, AGR%)
Figure 222 Sun Pharmaceutical Industries Ltd.: Net Revenue, 2018-2022 (US$ Million, AGR%)
Figure 223 Sun Pharmaceutical Industries Ltd.: R&D Expense, 2018-2022 (US$ Million, AGR%)

ページTOPに戻る

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのご注文・お問合せはこちらのフォームから承ります

本レポートと同分野（医薬）の最新刊レポート

Visiongain社の医薬・化学品分野での最新刊レポート

本レポートと同じKEY WORD（drugs）の最新刊レポート

本レポートと同じKEY WORDの最新刊レポートはありません。

よくあるご質問

Visiongain社はどのような調査会社ですか?

英国の調査会社ヴィジョンゲイン社（Visiongain）は、通信とエネルギーのほか、自動車や化学・医薬品、金属など、広範な市場を対象に調査を行っています。自動車市場については、市場全般に関する調査のほ... もっと見る

調査レポートの納品までの日数はどの程度ですか?

在庫のあるものは速納となりますが、平均的には 3-４日と見て下さい。
但し、一部の調査レポートでは、発注を受けた段階で内容更新をして納品をする場合もあります。
発注をする前のお問合せをお願いします。

注文の手続きはどのようになっていますか?

1)お客様からの御問い合わせをいただきます。
2)見積書やサンプルの提示をいたします。
3)お客様指定、もしくは弊社の発注書をメール添付にて発送してください。
4)データリソース社からレポート発行元の調査会社へ納品手配します。
5) 調査会社からお客様へ納品されます。最近は、pdfにてのメール納品が大半です。

お支払方法の方法はどのようになっていますか?

納品と同時にデータリソース社よりお客様へ請求書（必要に応じて納品書も）を発送いたします。
お客様よりデータリソース社へ（通常は円払い）の御振り込みをお願いします。
請求書は、納品日の日付で発行しますので、翌月最終営業日までの当社指定口座への振込みをお願いします。振込み手数料は御社負担にてお願いします。
お客様の御支払い条件が60日以上の場合は御相談ください。
尚、初めてのお取引先や個人の場合、前払いをお願いすることもあります。ご了承のほど、お願いします。

データリソース社はどのような会社ですか?

当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
世界各国の「市場・技術・法規制などの」実情を調査・収集される時には、データリソース社にご相談ください。
お客様の御要望にあったデータや情報を抽出する為のレポート紹介や調査のアドバイスも致します。

ジェネリック医薬品市場レポート：2024-2034

サマリー

目次

図表リスト

Summary

Table of Contents

List of Tables/Graphs

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

本レポートと同分野（医薬）の最新刊レポート

Visiongain社の医薬・化学品分野での最新刊レポート

本レポートと同じKEY WORD（drugs）の最新刊レポート

よくあるご質問

Visiongain社はどのような調査会社ですか?

調査レポートの納品までの日数はどの程度ですか?

注文の手続きはどのようになっていますか?

お支払方法の方法はどのようになっていますか?

データリソース社はどのような会社ですか?